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Mean Arterial Pressure in Acute Ischemic Stroke Study
Abstract
Background. There is little, if any, evidence available on the validation of blood pressure (BP)
measurements obtained in the acute care setting. Despite this, acute stroke practitioners trust and rely on
non-invasive blood pressure (NIBP) devices to guide acute ischemic stroke (AIS) patients’ treatment.
Although systolic blood pressure (SBP) has been found to be the most unreliable measurement displayed
on NIBP devices, treatment decisions for AIS are based on them. Today, 25 years after the FDA’s approval
of alteplase, practitioners continue to use BP parameters of 185/110 and 180/105 to guide the initiation
of alteplase bolus and infusion, although the shift to the use of NIBP devices challenges the validity of
these dated parameters. Theoretically, by inserting the inclusion and exclusion systolic and diastolic
blood pressure thresholds into the mean arterial pressure (MAP) equation, one could deduce the
exclusion threshold for MAP to be > 130. Furthermore, if a MAP of 130 mmHg were to be adopted as the
threshold for treatment, many patients who would otherwise be excluded, would receive alteplase
treatment. A clear understanding of MAP in relation to SBP and diastolic blood pressure (DBP) in patients
with AIS, which is now exclusively measured with NIBP devices, is critical for safe and effective alteplase
management. Study Aims. To understand agreement between SBP, DBP, and MAP measured by NIBP and
measured manually in alteplase-treated AIS patients. An additional secondary study aim was to
investigate the relationship between MAP and outcomes in alteplase-treated AIS patients. Methods. Two
trained examiners from three comprehensive stroke centers and four primary stroke centers measured
five sets of manual-derived BP and NIBP-derived SBP, DBP, and MAP in 95 acute ischemic stroke patients
treated with alteplase for a total of 475 paired sets of measures. The two examiners used a dual-auditory
stethoscope to ensure accuracy of the manual measures. To avoid interruption of acute stroke care, all
measurements occurred during the 24 hours following the alteplase infusion. The data was analyzed
using Bland-Altman analysis for measures of agreement. Results. Our study found no agreement in SBP,
DBP, and MAP for 475 paired manual and NIBP measurements, with SBP and MAP manual and NIBP
measures showing the least agreement between methods. Although DBP-paired measures did not agree,
they were in closer agreement than SBP and MAP measures on Bland-Altman (BA) analysis for measures
of agreement, and 44% of DBP measures fell within 5 mmHg of each other. NIBP measures were
consistently higher than manual measurements and differed from manual measurements as much as 50
mmHg for SBP, 40 mmHg for DBP, and 44 mmHg for MAP. We found that the higher the systolic blood
pressure, the greater the disagreement. Additionally, we analyzed the percentage of measurements that
fell within a difference of 5, 10, 15, and 20 mmHg for SBP, DBP, and MAP separately. For SBP, 39% of the
475 sets of measures fell within 5 mmHg and 62% fell within 10 mmHg. For DBP, 44% fell within 5mmHg
and 72% fell within 10 mmHg. For MAP, 34% fell within 5 mmHg and 62% fell within 10 mmHg.
Conclusion. Despite the widespread use of NIBP devices, few clinicians are familiar with their
fundamental operating principles and the potential for inaccuracies and disagreement between manual
and NIBP measurements. Clinically acceptable limits of agreement for SBP, DBP, and MAP in AIS patients
should be defined a priori based on clinical necessity, biological considerations, and treatment goals.
Additionally, our study takes an important first step in reframing AIS treatment context toward
consideration of MAP as a key measure to guide the initiation of alteplase treatment and ongoing patient
management. It is likely that stroke guidelines are silent regarding MAP because the information to
understand safe MAP levels in AIS patients during and after alteplase administration is lacking. The safe
MAP for AIS patients receiving alteplase treatment is not yet known, but work must continue in this area.

Document Type
Dissertation

Degree Name
Doctor of Philosophy (PhD)

Program
Nursing Science

Research Advisor
Anne W. Alexandrov, Ph.D.

Keywords
Neurosciences

Subject Categories
Medical Sciences | Medicine and Health Sciences | Nursing

This dissertation is available at UTHSC Digital Commons: https://dc.uthsc.edu/dissertations/527

UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER
DOCTOR OF PHILOSOPHY DISSERTATION

Mean Arterial Pressure in Acute
Ischemic Stroke Study

Author:
Mary Angela Grove

Advisor:
Anne W. Alexandrov, PhD

A Dissertation Presented for The Graduate Studies Council of
The University of Tennessee Health Science Center
in Partial Fulfillment of the Requirements for the
Doctor of Philosophy degree from
The University of Tennessee
in
Nursing Science
College of Graduate Health Sciences

July 2020

Copyright © 2020 by Mary Angela Grove.
All rights reserved.

ii

DEDICATION
I dedicate this dissertation to my loving husband, Sam Grove, for his
unconditional love, support, and belief in me during this journey and throughout our life
together.
To my friends and family, for their prayers and encouragement during the last five
years. A special thank you to my sister, Patty Antonelli, for always being there to offer
encouragement and assistance when it was most needed.
And to my parents, Iris C. Rabasca, Ph.D., an English Professor, and Michael J.
Rabasca, a history teacher―both humble, faith-filled, and life-long learners who taught
their six children the importance of loving God and family, and the value of higher
education.

iii

ACKNOWLEDGEMENTS
I would like to express my sincerest gratitude to my dissertation committee chair
Anne Alexandrov, Ph.D. I credit and thank Dr. Alexandrov for being the person who has
had the most significant impact on my career. She is an exceptional researcher,
innovator, nurse practitioner, and mentor who has fostered in me the skills, desire, and
belief in my ability to continue to grow as a researcher. I have benefited immensely from
her guidance, patience, and support, and I am incredibly fortunate to have worked closely
with her on this dissertation over the last five years.
I would also like to thank my other committee members. J. Carolyn Graff, Ph.D.,
has consistently provided me with guidance, support, and encouragement since our first
meeting in 2015. I am grateful for all she taught me regarding qualitative and mixed
methods research. I aspire to apply what I learned from Dr. Graff toward the
development of a mixed-methods study soon. Thank you also to Andrei Alexandrov,
M.D. I appreciate that he shared with me his knowledge, expertise, patience, and
encouragement in order that I might continue to grow as a professional researcher and
presenter. I also would like to thank Donna Hathaway, Ph.D., who as part of her
instruction of quantitative research, challenged me to consider different ways to look at
the research question in order to develop an impactful study design. And thank you to
Georgios Tsivgoulis, M.D., who introduced me to Bland-Altman analysis and taught me
that dedicating the time necessary to research, learn, and truly understand the issue at
hand leads to a solid foundation for future success.
I especially want to thank Mani Paliwal, who helped me understand statistical
methods and provided me untold hours of encouragement and support throughout my
Ph.D. journey. I am also extremely grateful to Beverly Howey who cheerfully and
enthusiastically shared with me advanced techniques in software programs (PowerPoint,
Excel, and Visio). Her contribution helped ensure an organized and efficient study
protocol process flow for the study investigators.
I must also recognize all the sub-investigators for this study. I appreciate their
participation, professionalism, and the time they dedicated to this study. I am fortunate to
have had the opportunity to work with them and am grateful for the friendships that
developed through our collaboration. I look forward to working with the subinvestigators again on future research projects. The sub-investigators were: Mani
Paliwal, MS, MBA; Jane Kaiser, MSN, APN; Eun Sun Koo, BSN, RN, CCRN, SCRN;
Danielle Howey, BSN, RN; Michele Galati, BSN, RN, SCRN, CMSRN; Bozena
Czekalski, MSN, RN, NP-C, SCRN; Jennifer Dumawal, DNP, RN, CCRN, CEN; Briana
DeCarvalho, MSN, RN, SCRN; Jackie Dwyer, MSN; Fran Latourette, MSN; Bradley
Pulver, MD; Robert Sweeney, DO; and Stephen Martino, MD.
And finally, I’d like to express my sincerest appreciation to Shirley Hancock for
her advice, encouragement, and the significant hours she spent ensuring the professional
presentation of this publication.

iv

ABSTRACT
Background. There is little, if any, evidence available on the validation of blood
pressure (BP) measurements obtained in the acute care setting. Despite this, acute stroke
practitioners trust and rely on non-invasive blood pressure (NIBP) devices to guide acute
ischemic stroke (AIS) patients’ treatment. Although systolic blood pressure (SBP) has
been found to be the most unreliable measurement displayed on NIBP devices, treatment
decisions for AIS are based on them. Today, 25 years after the FDA’s approval of
alteplase, practitioners continue to use BP parameters of 185/110 and 180/105 to guide
the initiation of alteplase bolus and infusion, although the shift to the use of NIBP devices
challenges the validity of these dated parameters. Theoretically, by inserting the
inclusion and exclusion systolic and diastolic blood pressure thresholds into the mean
arterial pressure (MAP) equation, one could deduce the exclusion threshold for MAP to
be >130. Furthermore, if a MAP of 130 mmHg were to be adopted as the threshold for
treatment, many patients who would otherwise be excluded, would receive alteplase
treatment. A clear understanding of MAP in relation to SBP and diastolic blood pressure
(DBP) in patients with AIS, which is now exclusively measured with NIBP devices, is
critical for safe and effective alteplase management.
Study Aims. To understand agreement between SBP, DBP, and MAP measured by
NIBP and measured manually in alteplase-treated AIS patients. An additional secondary
study aim was to investigate the relationship between MAP and outcomes in alteplasetreated AIS patients.
Methods. Two trained examiners from three comprehensive stroke centers and four
primary stroke centers measured five sets of manual-derived BP and NIBP-derived SBP,
DBP, and MAP in 95 acute ischemic stroke patients treated with alteplase for a total of
475 paired sets of measures. The two examiners used a dual-auditory stethoscope to
ensure accuracy of the manual measures. To avoid interruption of acute stroke care, all
measurements occurred during the 24 hours following the alteplase infusion. The data
was analyzed using Bland-Altman analysis for measures of agreement.
Results. Our study found no agreement in SBP, DBP, and MAP for 475 paired manual
and NIBP measurements, with SBP and MAP manual and NIBP measures showing the
least agreement between methods. Although DBP-paired measures did not agree, they
were in closer agreement than SBP and MAP measures on Bland-Altman (BA) analysis
for measures of agreement, and 44% of DBP measures fell within 5 mmHg of each other.
NIBP measures were consistently higher than manual measurements and differed from
manual measurements as much as 50 mmHg for SBP, 40 mmHg for DBP, and 44 mmHg
for MAP. We found that the higher the systolic blood pressure, the greater the
disagreement. Additionally, we analyzed the percentage of measurements that fell within
a difference of 5, 10, 15, and 20 mmHg for SBP, DBP, and MAP separately. For SBP,
39% of the 475 sets of measures fell within 5 mmHg and 62% fell within 10 mmHg. For
DBP, 44% fell within 5mmHg and 72% fell within 10 mmHg. For MAP, 34% fell within
5 mmHg and 62% fell within 10 mmHg.
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Conclusion. Despite the widespread use of NIBP devices, few clinicians are familiar
with -their fundamental operating principles and the potential for inaccuracies and
disagreement between manual and NIBP measurements. Clinically acceptable limits of
agreement for SBP, DBP, and MAP in AIS patients should be defined a priori based on
clinical necessity, biological considerations, and treatment goals. Additionally, our study
takes an important first step in reframing AIS treatment context toward consideration of
MAP as a key measure to guide the initiation of alteplase treatment and ongoing patient
management. It is likely that stroke guidelines are silent regarding MAP because the
information to understand safe MAP levels in AIS patients during and after alteplase
administration is lacking. The safe MAP for AIS patients receiving alteplase treatment is
not yet known, but work must continue in this area.
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CHAPTER 1.

INTRODUCTION

Overview
Each year in the United States, 795,000 persons experience new or recurrent
strokes. Early stroke symptom recognition is essential for seeking timely care.
Unfortunately, knowledge of stroke warning signs and risk factors in the United States
remains poor.1 Strokes account for one of every twenty deaths, are fifth among all causes
of death, and are the leading cause of serious long-term disability.2 Eighty-seven percent
are acute ischemic strokes (AIS) resulting from arterial blockage, whereas 13% are
classified as a hemorrhagic stroke that results from arterial rupture.3
Primary risk factors for stroke include high blood pressure, diabetes mellitus,
atrial fibrillation, high cholesterol, smoking, obesity, and family history.2 Of these risk
factors, blood pressure is the most powerful determinant of risk for both ischemic and
hemorrhagic stroke. Antihypertensive therapy is associated with a reduction in stroke
incidence. An average 10 mmHg decrease in systolic blood pressure (SBP) reduces the
risk of stroke by 41%.2
Landmark Study
The National Institute of Neurological Disorders and Stroke (NINDS) Tissue
Plasminogen Activator in Acute Ischemic Stroke Study4 took place from 1991-1994.
Investigators reported favorable functional outcomes at 90 days and at one year in
patients treated with intravenous recombinant tissue plasminogen activator (rt-PA) (now
known as “alteplase”). The results of this randomized, double-blind placebo-controlled
trial and the later European Cooperative Acute Stroke Study (ECASS)-35 serve
worldwide as the basis for evidence-based, guideline-directed treatment of AIS up to 4.5
hours from symptom onset.
In the original NINDS study,4 eligibility for enrollment included a clinical
diagnosis of ischemic stroke with a clearly deﬁned time of onset, a deﬁcit measurable on
the National Institute of Health Stroke Scale (NIHSS), and a baseline noncontrast brain
computed tomography (CT) scan that showed no evidence of intracranial hemorrhage.4
Since a fibrinolytic agent would be used to break up blood clots occluding brain arteries,
the investigators recognized the need for controlling severe hypertension to reduce the
risk of intracranial hemorrhage. The NINDS investigators selected blood pressure (BP)
parameters at the time of alteplase bolus to be less than 185/110 mmHg, with a further
reduction to less than 180/110 mmHg by the time the alteplase continuous infusion
began.4 Interestingly, these BP parameters were not established from pilot work but
instead were suggested with the thought that BP should not be maintained too low
because this may stifle flow through partially occluded vessels, thereby exacerbating
brain ischemia. Additionally, only manual sphygmomanometer BP monitoring was
allowed during the NINDS study because of concerns for bruising from noninvasive
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automatic oscillometric BP (NIBP) cuffs. Blood pressure monitoring by arterial line was
not advocated for the study because this approach would be impractical in an Emergency
Department setting, would increase time to treatment, and arterial puncture could result in
severe bleeding in an alteplase treated patient. Notably, criteria regarding a goal mean
arterial pressure (MAP) parameter was not included in the study.
MAP and Acute Ischemic Stroke
Since the publication of the NINDS study in 1995,4 NIBP devices have become
standard of care in hospitals in the United States and throughout most of the world.
These devices have an added feature of simultaneously displaying the patient’s heart rate
(HR) and MAP with the SBP and diastolic BP (DBP). Although NIBP MAP is readily
available, this parameter is disregarded by acute stroke practitioners because parameters
for MAP were never established. Stroke treatment guidelines are silent regarding MAP
because information to understand safe MAP values for maintenance of BP during and
after alteplase administration is lacking, and MAP in relation to stroke has had very little
attention because of widespread international acceptance of the NINDS study’s
established SBP and DBP treatment parameters.
Interestingly, MAP in patients with sepsis and septic shock has been studied
extensively and found to be a more useful measurement to guide treatment.6-9 While
perfusion of critical organs, such as the brain or kidney, may be protected from systemic
hypotension by autoregulation of regional perfusion, below a threshold MAP, tissue
perfusion becomes linearly dependent on arterial pressure.7,9 To date, findings
supporting the use of MAP in clinical practice, and in particular in patients undergoing
NIBP monitoring have not been adopted for stroke patients largely because previous
studies have been deemed irrelevant since they were not obtained in rt-PA-treated stroke
patients.
The acceptable limits for the parameters of SBP and DBP are informed by the
American Heart Association/American Stroke Association’s (AHA/ASA) 2018
Guidelines for the Early Management of Patients with Acute Ischemic Stroke,1,10 the
2019 Updates to the 2018 guidelines,10(p. e369) and by the NINDS Tissue Plasminogen
Activator in Acute Ischemic Stroke Study4. “Patients who have elevated BP and are
otherwise eligible for treatment with IV Alteplase should have their BP carefully lowered
so that their systolic BP <185mmHg and their diastolic BP is <110 mmHg before IV
fibrinolytic therapy is initiated.”1(p. e17),10(p. e369) Because BP parameters can vary
significantly throughout the 24 hours after alteplase treatment, patients that were initially,
“blood pressure in bounds” for alteplase, may have “out-of-bounds” periods where
hypertension may ensue placing the patient at high risk for post-treatment hemorrhagic
transformation. Therefore, as per the previously cited guidelines, acute stroke
practitioners are to manage the BP during and after alteplase therapy to maintain the BP
<180/105 mmHg.1,10
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Although MAP is readily available from NIBP devices commonly used by acute
stroke practitioners to monitor BP in AIS patients, no recommendations about MAP
parameters are made in current guidelines. Therefore, this parameter has not been of
interest to acute stroke practitioners. Theoretically, by inserting the exclusion and
inclusion SBP and DBP thresholds into the MAP equation of DBP + .333(PP), one could
deduce the exclusion threshold for MAP. By using this formula, the patient would be
excluded from receiving the alteplase bolus and infusion if their MAP is >135 mmHg and
>130 mmHg, respectively (Table 1-1). Furthermore, if a MAP of <135 mmHg is
adopted as the threshold for treatment, many patients who would otherwise be excluded,
would receive alteplase treatment. For instance, if a patient presents with an elevated,
exclusion SBP of 210 and within-guideline DBP of 88, applying the equation DBP +
.333(PP), their MAP would be 130 mmHg. Additionally, if the patient’s presenting SBP
is within guidelines for treatment at 170 mmHg but with an elevated, exclusion DBP of
106 mmHg, their MAP would also be 130 mmHg. In other words, many combinations of
SBPs and DBPs could mathematically produce a MAP of 130 mmHg. However, many of
these may be outside the traditional BP treatment parameters that state SBP should be
less than 180 mmHg, and DBP should be less than 105 mmHg (Table 1-2).
Today, 21 years after the U.S. approval of alteplase, acute stroke practitioners
continue to use the original parameters proposed in the NINDS study.4 However, their
shift to the use of NIBP devices challenges the validity of these dated parameters.
Firstly, the MAP is considered the most reliable measurement from an NIBP device. In
fact, the SBP and DBP measurements displayed on these devices are derived from the
MAP using a proprietary algorithm. Secondly, there is much heteroscedasticity among
study results that examined agreement between SBP, DBP, and MAP parameters derived
from manual sphygmomanometry/cuff and NIBP devices.
Of the few papers that address MAP and AIS in general,11-14 none address MAP
in relationship to alteplase treatment guidelines. There is a critical need to understand
MAP on NIBP monitoring in patients undergoing alteplase treatment, to inform clinical
practice of acceptable parameters that may be more beneficial than NIBP derived SBP
and DBP values, which show little agreement to actual pressures.
Study Aims
Primary Study Aims
1. Understand agreement between SBP and DBP measured by NIBP device and
manual sphygmomanometry in AIS patients treated with alteplase.
2. Understand agreement between MAP measured by NIBP device and calculated
MAP (from manually obtained SBP and DBP) in AIS patients treated with
alteplase.
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Table 1-1.
MAP in relation to current “in-bounds” SBP and DBP for initiation of
alteplase bolus and alteplase infusion in acute ischemic stroke patients.
Initiation of
Alteplase
Bolus
Infusion

Systolic Blood
Pressure
(SBP)
<185
<180

Diastolic Blood
Pressure
(DBP)
<110
<105

Pulse Pressure
(PP)
75
75

Mean Arterial
Pressure
(MAP)
<135
<130

Notes: MAP = DBP + .333(PP); “in-bounds” = blood pressure threshold based on current
acute ischemic stroke guidelines for initiation of alteplase bolus and infusion.

Table 1-2.
MAP in relation to theoretical combination of “in-bounds” and “outof-bounds” SBP and DBP for initiation of alteplase infusion in acute ischemic stroke
patients.
Initiation of
Alteplase
Infusion
Infusion
Infusion
Infusion

Systolic Blood
Pressure
(SBP)
170
210*
166
220*

Diastolic Blood
Pressure
(DBP)
106*
88
110*
80

Pulse Pressure
(PP)
66
122
56
140

Mean Arterial
Pressure
(MAP)
128
129
129
127

Notes: MAP = DBP + .333(PP); * = “out-of-bounds” blood pressure based on current
acute ischemic stroke guidelines for initiation of alteplase infusion.
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Secondary Study Aim
1. Investigate the relationship between MAP and outcomes in alteplase treated AIS
patients
Significance of Study
Stroke Centers are evaluated and ultimately certified by how closely the
interventions they provide to AIS patients are in agreement with the Guidelines for the
Early Management of Patients with Acute Ischemic Stroke.1,10 The American Heart
Association/American Stroke Association (AHA/ASA) publication is regularly updated
to ensure the guidelines stay current with findings from new clinical research that
influence AIS treatment. In the 2018 guidelines,1 the panel added the recommendation
that hypotension and hypovolemia should be corrected to maintain systemic perfusion
levels necessary to support organ function.
In instances where supporting evidence based on clinical trial research is not
available, recommendations from the panel of subject matter expert authors are made on
the basis of pathophysiological reasoning and expert practice experience. If there are no
clinical trials to inform recommendations, the panel applies rules of evidence and
strength of recommendations to inform the guideline.15 The panel’s recommendation for
safe BP parameters in patients with AIS is an example of the use of expert opinion
because of the lack of supporting evidence from clinical research. This may explain why
current stroke guidelines1,10 remain essentially noncommittal with regard to evidencebased recommendations:
The blood pressure (BP) level that should be maintained in patients
with AIS to ensure best outcome is not known. Some observational
studies show an association between worse outcomes and lower BPs,
whereas others have not. No studies have addressed the treatment of
low BP in patients with stroke. In a systematic analysis of 12 studies
comparing colloids with crystalloids, the odds of death or dependence
were similar. Clinically important benefits or harms could not be excluded.
There are no data to guide volume and duration of parenteral fluid delivery.
No studies have compared different isotonic fluids.1(p. 35)
These statements reflect the heterogeneity of AIS, and that systemic vascular and
cardiac pathology may require and tolerate very different thresholds of pressure to
maintain and/or enhance perfusion.
Symptomatic Intracerebral Hemorrhage
For BP management during fibrinolytic therapy, the AHA/ASA stroke guidelines
provide more specific guidance. To inform their recommendations, guideline authors
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used methodology from the 1991-1995 NINDS study,4 as well as results from research
conducted since the NINDS study,16 showing that elevated BP levels before or during
alteplase infusion may be related to adverse outcomes, including a higher risk of
symptomatic intracranial hemorrhage (sICH) and a lower likelihood of complete
recanalization and three-month favorable functional outcome.17 Several studies, in
particular, have shown an association between elevated systolic BP (SBP) and sICH18-20,
with the best outcomes associated with an SBP of 141 to 150 mmHg.15,20
Of note, sICH remains the most feared complication of alteplase treatment21 with
a reported 50% mortality.22 It is defined as a local or remote parenchymal hemorrhage
type 2 noted within 36 hours post-alteplase treatment, in combination with a National
Institute of Health Stroke Scale (NIHSS) increase of 4 points or more from baseline or
from the lowest NIHSS value measured, or clinical worsening that leads to death.18,21 In
the NINDS study,4 the incidence of sICH was 6.4%; however, the definition used for
sICH was very different from the current definition listed above. Subsequent studies that
used the new definition show a lower sICH incidence that has not exceeded 3% in large
clinical trials.18,19,23,24 The risk for sICH after alteplase administration is clearly
associated with BP parameters.16 Therefore, the AHA/ASA guidelines recommend
maintaining BP <180/105 mmHg and delaying the administration of aspirin until 24
hours after alteplase treatment. However, in the presence of concomitant conditions for
which such treatment given in the absence of alteplase is known to provide a substantial
benefit or withholding such treatment is known to cause substantial risk, earlier
administration of aspirin and/or other antiplatelet therapy may be considered.1
Elevated blood pressure is common during acute ischemic stroke15 and is often
higher in acute stroke patients with a history of hypertension than in those without
premorbid hypertension. In an observational study, SBP was >139 mmHg in 77% and
>184 mmHg in 15% of patients on arrival to the ED.25 During the acute phase of
ischemic stroke BP may decrease spontaneously, starting within 90 minutes after the
onset of stroke symptoms,15 however, this has not been well studied in relation to
vascular imaging changes over time. In other words, in cases where the residual clot is
not retrieved or lysed, BP may remain elevated in an attempt to augment downstream
perfusion through collateral arterial channels. But again, to fully understand changes in
BP in relation to clot burden, more work in this area is needed.
Mean Arterial Pressure
Mean arterial pressure (MAP) is the average arterial pressure during one cardiac
cycle. It is considered a better indicator of perfusion to vital organs than SBP.26 Normal
MAP values generally lie between 70 and 110 mmHg, with recent guidelines
recommending maintenance of MAP at more than 65 mmHg to ensure adequate tissue
perfusion and to avoid shock.9 A MAP of 60 mmHg provides the internal organs with
the necessary supply of blood, but prolonged hypotension with a MAP of less than 60 to
65 mmHg is associated with poor outcomes.8 Perfusion of critical organs such as the
brain or kidney is safeguarded by autoregulation in the event of systemic hypoperfusion,
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however below a MAP threshold, tissue perfusion becomes linearly dependent on the
arterial pressure to prevent shock.9 In ischemic states, such as AIS, the loss of
autoregulatory capacity results in passive vasomotor dilation, making blood flow
passively dependent on mean arterial pressure.27
Oscillometric Blood Pressure Monitors (Non-invasive Blood Pressure Devices)
The DINAMAP brand of oscillometric blood pressure monitors was introduced in
the mid-1970s. DINAMAP is an acronym for “Device for Indirect Noninvasive
Automatic Mean Arterial Pressure”.28 The first generation of these devices only
measured MAP. Subsequent models added SBP and DBP as well as HR measurements.29
These devices were designed, in part, to answer the need for more accurate measurement
of BP, allowing clinicians to non-invasively monitor and maintain acceptable MAP
parameters, especially in critically ill, hypotensive patients. Since their introduction,
validity and reliability testing has been conducted, first on animals, then on humans.28,30
By the late 1980s and early 1990s, after 20 plus years of research, NIBP devices achieved
widespread trust as acceptable measures of blood pressure, despite variability in study
results which examined accuracy and/or agreement between NIBP device measurements
of SBP, DBP, and MAP and arterial line monitoring measurements31-35 the gold standard
for BP and MAP accuracy,36-38 and between manual sphygmomanometer readings.31,39-43
Studies have shown that oscillometric devices overestimate SBP, and
underestimate DBP compared with sphygmomanometers.39,41,42 Therefore, it is very
possible that current alteplase treatment is being managed at pressures that are, in reality,
lower than thresholds set by the original NINDS study.4 This is significant because poor
management of blood pressure in AIS patients is associated with worse outcomes.15
Additionally, since NIBP cuffs deflate at a manufacturer-specific speed that
assumes a regular pulse,44 use of NIBP monitoring is not recommended in patients with
atrial fibrillation or other highly irregular heart rhythms, because the device has been
found to be highly inaccurate.28 However, widespread adoption of the device around the
world in numerous patient populations demonstrates that this advice is largely ignored.
Conceptual Framework
Ischemic Penumbra
Through a series of events called the ischemic cascade, an AIS causes one zone of
injury and one zone of potential injury, referred to respectively as: 1) the ischemic core
and 2) the ischemic penumbra. The ischemic core is the area of the brain most affected
by severe ischemia, with most tissue in the region irreversibly injured and, ultimately,
infarcted. Ischemic penumbra, of which the conceptual framework is the focus of this
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study, is brain tissue potentially destined for infarction, but not yet irreversibly
injured.17,45
Ischemic Cascade
The ischemic cascade, rather than a chain of events, is actually multiple processes
occurring simultaneously. Cell hypoperfusion and resulting cell hypoxia cause neurons
to lose their ability to create energy in the form of adenosine triphosphate (ATP) through
aerobic metabolism. With the marked reduction/absence of oxygen, energy is instead
produced by anaerobic metabolism, which produces approximately 15 times less energy
than that produced by ATP. A by-product of anaerobic metabolism is lactic acid, which
in high enough quantities, disrupts the normal acid-base balance within brain cells (glial
cells and neurons).46 Consequently, ATPase-dependent ion transport mechanisms become
dysfunctional, contributing to increased intracellular and mitochondrial calcium levels,
cell swelling, rupture, and, ultimately, cell death.47 Simultaneously, the sodium and
calcium pump within the cells stops functioning normally, resulting in an influx of
calcium in the cell that stimulates neuronal depolarization. This excessive depolarization
causes excitotoxicity48 and an excessive release of neurotoxic glutamate from presynaptic
nerve terminals.49
Cell death ensues through a variety of mechanisms, including excitotoxicity, as
noted above, as well as through ionic imbalance, oxidative/nitrosative stress, inflammation, apoptosis, and peri-infarct depolarization.50 Under normal circumstances,
cerebral blood flow (CBF) is maintained at a relatively constant rate of 50 mL/100 g/min.
As cerebral perfusion pressure (CPP) decreases, CBF gradually declines. When CBF
decreases to less than 20 to 25 mL/100 g/min, a massive loss of oxygen and glucose, two
vital nutrients for neurons and supportive glial cells, occurs. Below a CBF of 10 mL/100
g/min, neuronal depolarization occurs and, within a few minutes, will result in the death
of core neurons and causing necrosis51 unless CBF is restored.52
Disruption of the Blood Brain Barrier
The Blood-Brain Barrier (BBB) separates the bloodstream from tissue in the brain
and central nervous system. This protective barrier is vital for the prevention of infection
and injury. Four to six hours after an AIS, the blood-brain barrier starts to break down,
resulting in an inflammatory reaction in the ischemic area around the infarct. Vasogenic
edema occurs from proteins and water leaking out of endothelial cells in the capillaries
and into the extracellular space. This edema adds to cytotoxic edema, which is already in
the area and can result in a mass effect where brain swelling displaces surrounding brain
tissue. The swelling increases over a few days and peaks 3-5 days post-stroke.53 The
enhanced permeability of the vascular wall, because of prolonged ischemia and hypoxia
caused by vascular compression, greatly increases the chances of hemorrhagic
transformation, making cautious BP management critically essential.54
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The occurrence of sICH after administration of alteplase may also be associated
with disruption of the blood-brain barrier. Although oxygen to brain cells is restored
upon reperfusion after administration of alteplase, a surge in the generation of reactive
oxygen species occurs, and pro-inflammatory neutrophils infiltrate ischemic tissues
actually exacerbating the ischemic injury. Thus, consideration of the integrity of the
blood-brain barrier should also guide BP treatment decisions.22
Prolonged ischemia leads to brain cell death. While neurons die, they release
damage-associated molecular patterns (DAMPs), which are signals which trigger the
inflammatory response by activating inflammatory cells called macrophages.
Macrophages cause more inflammation by activating immune cells. Collectively, this
stimulates liquefactive necrosis. Neutrophils in the area release digestive enzymes called
hydrolases that breakdown dead cells and create a cavity of soft, liquefied necrotic cell
debris.53 If the stroke and resulting necrotic area are small, it can be contained and
removed by macrophages. A larger necrotic area creates a large cavity in the brain,
which is permanent and will not regenerate, ultimately filling with cerebrospinal fluid
once the dead tissue has been carried off.53
Cell processes and changes during the ischemic cascade, where different areas
within the ischemic region evolve into irreversible brain injury over time, were first
identified in animal studies.55-58 Additional studies56,59-63 involving AIS patients using
CT, magnetic resonance imaging and angiography (MRI and MRA), and post-mortem
evaluation of brain tissue, contributed to the development of the ischemic penumbra
conceptual framework, of which the construct is the Ischemic Cascade. Concepts include
the Ischemic Core, Ischemic Penumbra, Cerebral Autoregulation, Cerebral Perfusion
Pressure, Cerebral Blood Flow, and Blood Pressure (Appendix A).
Assumptions for the Penumbral Conceptual Framework are: 1) Penumbra is
ischemic brain tissue potentially destined for infarction, but not yet irreversibly
injured;17,45,61 2) Cerebral blood flow is dependent on vascular conductance and mean
arterial pressure;64,65 and 3) The absence of autoregulatory capabilities in the ischemic
penumbra, the area which is at risk of being recruited into stroke, results in vasomotor
relaxation with passive vascular dilation, a state that is fully dependent on mean arterial
pressure to ensure perfusion.65
Because the penumbra is hypoperfused tissue surrounding the ischemic core, in
which blood flow is too low to maintain electric activity but sufficient to preserve ion
channels, the area is subjected to the wave of deleterious metabolic processes66 which
occurs during the ischemic cascade (excitotoxicity, spreading depression, oxidative
stress, and inflammatory response), however, since the penumbra is still potentially
salvageable, it is the target of acute therapies.17,67
Findings show that this evolution is most critically linked to the severity of the
decline in CBF, which is dependent on vascular resistance and arterial BP. Cerebral
autoregulation is the inherent ability of blood vessels to keep CBF relatively constant
over a wide range of systemic BP levels by means of complex myogenic, neurogenic, and
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metabolic mechanisms.64 However, because cerebral autoregulation is lost within the
ischemic penumbral territory, understanding BP in relation to penumbral salvage with
therapies such as alteplase is essential to optimizing patient outcomes in acute ischemic
stroke.
The penumbral concept states that different areas within the ischemic region
evolve into irreversible brain injury over time. It is necessary to ensure adequate CBF in
the penumbral region of vasomotor relaxation while protecting tissue that is friable and
vulnerable to hemorrhage because of ischemic injury. Therefore, a clear understanding
of MAP in relation to SBP and DBP in patients with AIS, which is now exclusively
measured with NIBP devices, is critical for safe and effective alteplase management.
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CHAPTER 2.

LITERATURE REVIEW

Blood Pressure in Acute Ischemic Stroke (AIS)
Ischemic stroke can be divided into two broad groups of patients, those with large
vessel occlusions (LVO), who make up approximately 30% of cases, and those with
small vessel (lacunar) strokes, who make up a considerably larger group.27 LVO can
occur from embolization from a proximal source or less commonly in situ
atherosclerosis,27,68 both of which lead to an abrupt fall in regional cerebral blood flow
(CBF).68
Large Vessel Occlusion (LVO) and Ohm’s Law
In a small observational study, cases of LVO treated with alteplase with higher
systolic blood pressure (SBP) on presentation were associated with lower
revascularization rates.69 This finding is well supported by Ohm’s law of electricity,
which has been applied to hemodynamics. Ohm’s original work suggested the following:
(U (voltage) = I (current) × R (resistance).70 Applying Ohm’s law to the pathophysiology
of vessel occlusion, where BP (pressure differences) is analogous to voltage, cardiac
output (CO) to current, and systemic vascular resistance (SVR) to resistance,70 the
hemodynamic equation is expressed as Q (blood flow) = (P1 – P2 (pressure difference)) /
R (resistance). In other words, the difference between pressures at two different points,
divided by resistance, produces blood flow. Therefore, higher SBP in LVO patients may,
in fact, represent persisting occlusion with an attempt to overcome a high resistant state.
Small Vessel Occlusion (Lacunar Strokes)
Lacunar strokes are small (0.2 to 15 mm in diameter) noncortical infarcts caused
by occlusion of a single penetrating branch of a large cerebral artery.71 The primary risk
factor for lacunar strokes is hypertension72. Hypertension results in lipohyalinosis, a
segmental arteriolar wall disorganization that causes wall thickening and diameter
reduction of the small vessel.71 Although no large-scale trial has systematically studied
blood pressure (BP) management in either LVO or lacunar strokes to provide clear
guidance, recent findings in lacunar stroke patients suggest that it is likely safe to lower
BP well below the guideline-recommended values.73,74
Blood Pressure Management in Acute Ischemic Stroke
With each update in the Guidelines for the Early Management of Patients With
Acute Ischemic Stroke,1,10 recommendations regarding optimal BP in AIS patients to
ensure the best outcome have been noncommittal. Both the 2018 guidelines1 and the
2019 updated guidelines10 state that an absolute target BP level for AIS patients is not
known. This lack of absolutes naturally leaves room for clinician interpretation and
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thusvariation among acute stroke centers’ BP management. Illustrating this, a
retrospective study75 that sought to describe practice patterns for BP management in
patients with AIS among emergency department (ED) physicians in Midwest academic
and community hospitals found that antihypertensive therapy was often given despite
patients not meeting guideline treatment criteria. Additionally, reduction in SBP
exceeded guideline recommendations in one in four cases, while one in three cases that
met guideline criteria for BP treatment did not receive antihypertensives.75
Blood Pressure Management in Acute Ischemic Stroke Patients Receiving Alteplase
For AIS patients receiving alteplase, clinical guidelines for SBP and diastolic
blood pressure (DBP) parameters have been specified and are based on the limits
established for the NINDS rt-PA Stroke Study.4 The guidelines state that patients who
have elevated BP and are otherwise eligible for treatment with intravenous alteplase
should have their BP carefully lowered to a systolic BP <185 mmHg and diastolic BP
<110 mmHg prior to the alteplase bolus. In addition, the BP should be further lowered to
<180 mmHg SBP and <105 mmHg DBP prior to initiation of the alteplase continuous
infusion.1 Strict control of BP is essential in the alteplase-treated patient, and BP
protocol violations are independently associated with a higher likelihood of sICH and
worse patient outcome. In a retrospective cohort study that analyzed 510 patients with
ischemic stroke treated with alteplase within 3 hours from stroke onset over a previous
10-year period, sICH occurred in 31 patients (6.1%);16 BP protocol violations were
present in a total of 63 patients (12.4%) and were more frequent in patients with sICH
(26% versus 12%; P = 0.019). However, as discussed previously, the BP parameters cited
in the guidelines were not derived through systematic study but instead were based on the
expert consensus of the NINDS rt-PA Stroke Study trialists.
Mean Arterial Pressure in Acute Ischemic Stroke Patients
Although BP is one of the easiest cardiovascular measures to quantify, it only
provides indirect information regarding the patient’s cardiovascular status.70 Because
MAP is the average effective arterial pressure that propels blood through the vasculature,
its value is important in the management of patients with systemic blood flow limitations,
thus making it a more useful and common parameter in systemic conditions for
assessment of tissue and organ perfusion.27,70 However, in previous or current stroke
guidelines, goal MAP parameters have never been set or even mentioned despite its
significant effect on CBF in the face of cerebral autoregulatory collapse.27 Moreover,
and ironically, MAP is not utilized for monitoring patients’ response to care despite the
fact that it is readily available to providers with point-of-care non-invasive oscillometric
BP (NIBP) devices. Furthermore, no studies have yet to investigate the relationship
between MAP and outcomes in AIS patients who have received alteplase. Interestingly,
of the few papers that address MAP and AIS in general, none address MAP in
relationship to treatment guidelines.
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Calculation of Mean Arterial Pressure
The mathematical formula for MAP in patients with central70 and arterial line
invasive monitoring is: (CO x SVR) + central venous pressure (CVP). In patients
without central monitoring, MAP can be calculated from blood pressure cuff
measurements using the empirical formula which states: MAP equals the sum of diastolic
pressure (DP) and one-third of the pulse pressure (PP), where PP is the difference
between the systolic and diastolic pressure.76,77 Thus MAP = DP + 0.333(PP). This
standard equation assumes that diastole persists for 2/3 and systole for 1/3 of each cardiac
cycle.76
Ischemic Penumbra
The concept of an ischemic penumbra is based on the theory that downstream
perfusion from an infarct determines the fate of tissue lying in that region. Within that
downstream region, a “potentially viable” area, the ischemic penumbra, that is likely
most relevant to the degree to which patients with LVO stroke recover from their
ischemic event.
The human brain constitutes only 2% of the body weight but receives 15% of total
cardiac output.78 Autoregulation is the mechanism responsible for maintaining blood flow
relatively constant in the brain and other vital organs and, as such, plays a critical role in
maintaining blood flow and tissue viability to the brain during AIS. Furthermore, its role
in maintaining the viability of the ischemic penumbra could determine the degree of
permanent disability.
Cerebral autoregulation (CA) is best described by the relationship between MAP
and mean CBF.79 In normal states of perfusion, CA enables relatively constant CBF
despite variation in arterial pressure, actively constricting when pressures are elevated to
limit blood flow, and dilating arterial segments when MAP drops to maximize blood
flow.80 In the case of AIS, increased intracranial pressure (ICP) is rare because of
cerebral atrophy that affords room within the skull. When increased ICP occurs, it is
generally a late event occurring between 48-96 hours post-stroke onset. Therefore,
cerebral perfusion pressure (CPP), which is the product of MAP less ICP, or MAP-ICP =
CPP, is generally expected to be no more than 10-15 mmHg less than MAP in AIS.
Because it is energy dependent, CA is generally well maintained within a MAP of 60-150
mmHg.81 However, in the event of an AIS, CA is dramatically impaired due to failure of
cellular adenosine triphosphate (ATP) dependent systems, resulting in acidosis and
passive vasomotor relaxation that produces maximal arteriole dilatation.82 The
consequence of this dilatation is that CBF becomes passively dependent on MAP.83 In
the case of LVO stroke, precipitous drops in BP may further devastate perfusion of
penumbral tissue, thereby recruiting it into infarction.
It is difficult to understand why MAP has been a neglected value in patients with
stroke. Most stroke patients today are managed using NIBP monitoring, and even though
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these devices provide a MAP value, it is largely ignored by stroke practitioners. Given
the physiologic significance of MAP, an improved understanding of its relevance in the
management of AIS is warranted.
MAP in Relation to Systemic Conditions
MAP in Sepsis
Optimal MAP in sepsis has been widely studied.6,8 During standard treatment for
septic shock, the most important hemodynamic variables predicting 30-day outcomes are
MAP and lactate for the first 6 hours and MAP, mixed venous oxygen saturation (SvO2),
and CVP for the first 48 hours. The best predictive threshold levels for mortality in
sepsis were 65 mmHg for MAP and 70% for SvO2.8 A retrospective study of 111
patients found that a target MAP of 65 mmHg is usually sufficient in patients with septic
shock. However, a MAP of around 75 to 85 mmHg may reduce the development of acute
kidney injury in patients with chronic arterial hypertension.6 Based on results of these
and other studies examining optimal MAP while on vasopressor agents, the Society of
Critical Care Medicine’s Surviving Sepsis International Guidelines for the Management of
Patients with Sepsis and Septic Shock: 20167 gave a strong recommendation for an initial
target MAP of 65 mmHg in patients with septic shock. Overall recommendations suggest
that a target MAP of 65 mmHg, when compared to higher MAP targets (i.e., 85 mmHg),
results in lower risk of atrial fibrillation, lower vasopressor requirements, and similar
mortality among patients with septic shock.7
MAP during Cardiac Surgery
Currently, there is no consensus for the optimal MAP for patients during
cardiopulmonary bypass (CPB),84 but based on results from a series of studies; the
accepted range appears to lie between 50 – 80 mmHg. In a 1990 study of 504 patients’
neurologic and renal outcomes in relation to MAP during coronary artery bypass grafting,
a target MAP of >50 mmHg was recommended, with findings that this MAP did not
adversely affect renal or cerebral function85. However, in a 1995 randomized trial
comparing intraoperative high versus low MAP during CPB, patients who were
maintained at a MAP of 80 mmHg had significantly less (8.1%) morbidity and mortality
than those managed at usual MAPs of 50–60 mmHg.86 In 1998, researchers assessed the
efficacy and safety of the pharmacological protocol used to achieve and maintain target
MAP to 80 mmHg in the 1995 study and reported that findings support the protocol as
both efficacious and safe.87
In 2007, researchers further expanded on the findings of the 1995 study by
evaluating whether tailoring the MAP target for the period of CPB to the patient’s usual
(pre-surgery) MAP would reduce major morbidity and mortality and improve quality of
life more than using a target MAP of 80 mmHg for all patients. They found there were
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no statistically significant differences in the combined outcome of mortality, cardiac,
neurologic or cognitive complications, and deterioration in the quality of life.88
The John Hopkin’s Textbook of Cardiothoracic Surgery89 advises that MAP range
during CPB lies between 50 and 80 mmHg, based on patient’s coexisting conditions:
Perfusion of the brain is normally protected by autoregulation, which
appears to be lost somewhere between 55 and 60 mmHg during CBP at
moderate hypothermia and 24 percent hematocrit. This pressure is thus
generally regarded to be the lowest safe pressure for routine CBP. In
older patients, who may have vascular disease and/or hypertension,
mean arterial blood pressure is generally maintained between 70 and
80 mmHg at 37°C. Higher pressures are undesirable because
collateral blood flow to the heart and lungs increases blood in the
operative field.89(p. 348)
Recommendations on setting MAP parameters in cardiac diseases can be
summarized as “tailored to the vascular dynamics of the patient.” This is logical in that
hemodynamic diseases are highly heterogeneous, often requiring very different
approaches to management to ensure optimal blood flow. Given that AIS is more similar
to myocardial infarction than to other neurologic diseases, once MAP is systematically
studied as a measure of flow and subsequently used more routinely to monitor BP, the
resulting data may similarly suggest establishing an acceptable range rather than a single
target value or use of a tailored approach.
Non-Invasive Blood Pressure (NIBP)
As described earlier, (CO x SVR) + CVP = MAP.90 However, an arterial line and
pulmonary artery catheter (PAC) are needed to directly measure CO, SVR, and CVP.
Such instrumentation requires invasive procedures that would delay care to patients
warranting time-sensitive emergent stroke treatment. Additionally, the risk of bleeding in
the alteplase treated patient with an arterial line and PAC would be substantial.
Therefore, the use of non-invasive technology has become the standard of care for the
management of acute stroke patients.
Original research on the indirect oscillometric measurement of BP dates to
1876,91 years before Korotkoff (1905) described the sounds that measure systolic and
diastolic arterial pressure levels for the auscultatory method.92-95 Research and
development for NIBP oscillometric measurements increased in the 1960s as a method to
measure BP on animals, whose Korotkoff sounds are difficult to detect.93 In 1969, Posey
and Geddes showed that the point of maximum oscillation corresponds to true MAP,92,96
with continued work showing points in the oscillometric envelope that correlated not only
with MAP but also with SBP and DBP. SBP correlated with a cuff pressure in the
oscillogram when the oscillations reached about 50% of their ultimate peak, and DBP
correlated with oscillations that were at about 80% of peak.96 In 1979, an early NIBP
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device was tested using measures on the bicep and ankle in 28 studies of 17 subjects with
intra-arterial catheters. Investigators concluded that NIBP produced good results
regardless of clinical condition.29 With the award of a US patent in 1982 for the
DINAMAP (a synonym for Device Noninvasive Measurement of Arterial Pressure) to
Ramsey III (Johnson & Johnson, assignee),97 automatic oscillometric point of care patient
monitoring entered the clinical arena. The original device only measured and displayed
MAP. In 1988, a second patent was awarded to Ramsey III et al. (Critikon, assignee), for
a newer generation DINAMAP capable of measuring and displaying SBP and DBP along
with MAP.98
NIBP devices in use today determine MAP by measuring cuff pressure
oscillations as the cuff pressure is reduced by discrete increments.29 The small
oscillations of intra–cuff pressure, which are caused by heartbeat–induced pulse volume
changes, are sensed by the cuff and measured by a pressure transducer.99 Cuff deflation
in discrete increments, instead of continuously, allows the oscillation data obtained at
each cuff pressure to be tested for artifacts and averaged, greatly enhancing artifactrejection ability.29 MAP is selected as the lowest cuff pressure at which the oscillation
amplitude is a maximum.29 SBP and DBP values are then algorithmically derived from
the MAP99,100. Because it correlates directly with the maximum oscillations detected by
the system, the MAP is accepted as the most accurate value derived from NIBP
measurements.32 Since cuff pressure oscillations continue when cuff pressure falls
beneath diastolic blood pressure, the endpoint for diastolic pressure is indistinct.31
Like any instrument, the usefulness of its measurements is dependent first upon
its validity and second its reliability. This is especially so for NIBP measures such as
SBP and DBP that are derived from the MAP reported on the device. Differing clinical
validation protocols for automated non-invasive oscillometric devices have been
established by the American National Standards Institute (ANSI) and the US Association
for the Advancement of Medical Instrumentation (AAMI), the International Organization
for Standardization (ISO), the British Hypertension Society (BHS), and the European
Society of Hypertension (ESH) Working Group on Blood Pressure (BP)
Monitoring.101,102 ANSI/AAMI first published their joint standards and recommended
practices in 1987,103 with periodic updates released since then. The most recent version
of the ANSI/AAMI/ISO standard was released in 2019.104
The ANSI/AAMI/ISO protocol determines the accuracy of BP monitoring devices
using the mean error and the standard deviation of error obtained from 255
measurements. This standard requires the mean error to fall within 5 mmHg and a
standard deviation of error to fall within 8 mmHg.103-105
In the “interest of science, patients, consumers, and manufacturers”, the AAMI,
ESH and ISO experts agreed to develop a universal standard protocol for device
validation.101 Consensus is based on the evidence from previous validation studies using
the AAMI, BHS, ESH-IP, and ISO protocols, new statistical analyses on power of study
sample and subgroups, and expert opinion.101 Current key aspects of the validation
procedure are that at least 85 subjects are required for the validation study, the
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auscultatory standard is retained for reference BP measurement with measurements taken
simultaneously by 2 trained observers blinded to each other’s readings and to the
measurements taken with the test device.103 As soon as the AAMI/ESH/ISO standard is
fully developed, it will be regarded as the single universal standard and will replace all
other previous standards/protocols. This was expected to be finalized in 2018,101,106
however, as of this writing, the full document is not yet published.
Clinicians should understand that NIBP measurements are the end-product of
company-owned proprietary computer algorithms. Therefore algorithms, testing, and
validation procedures differ from one device to another103 and are scattered in many
different publications or patents.105 Most practical algorithms used in commercially
available devices are closely guarded trade secrets that are not subject to independent
critique and validation. Hence the best way to determine systolic and diastolic arterial
pressures from cuff pressure oscillations remains an open scientific problem.31 Because
of this situation, claims and findings of accuracy and agreement for one NIBP device
brand cannot be generalized to other brands.
Studies of Agreement
Benefits of oscillometric measurement include the elimination of observer
variability107 and the need for a stethoscope, which makes NIBP less susceptible to
external noise (excluding low-frequency mechanical vibration).108 Use of NIBP
monitoring has become a substitute for invasive intra-arterial BP measurements, reducing
bleeding and infection risk, and these devices are now found throughout the hospital.36
Additionally, NIBP monitoring may also decrease erroneous BP measurements as a result
of an auscultatory gap, which is often present in older patients with a wide pulse pressure.
With auscultatory gaps, Korotkoff sounds may become inaudible between systolic and
diastolic pressure, and reappear as cuff deflation continues; this may also occur because
of fluctuations of intra-arterial pressure and is likely in subjects with target organ
damage.109
Study findings31-33,110-112 vary with regard to agreement between BP measures
from an NIBP device compared to measures from an arterial line and manual
sphygmomanometer. Per the 2013 ANSI/AAMI/ISO standard,103 for clinical use, the
current acceptable limit of the difference is approximately 5mmHg.43,99,103 Many studies
used these limits to analyze and report findings of accuracy.
NIBP Agreement with Arterial Line Measurement
Concerning agreement between NIBP device and arterial line measures, both
animal
and human studies have shown that NIBP devices accurately and consistently
measure MAP with acceptable agreement of the displayed MAP from arterial line
monitoring.31-33 MAP has also been found to be more reliable than the displayed SBP
and DBP readings.43 Interestingly, diastolic NIBP values have shown closer agreement
33,111,112
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with arterial line diastole, whereas NIBP systolic pressures may differ considerably from
arterial line systole.33
In anesthetized surgical patients, NIBP devices showed an acceptable agreement
and were interchangeable with invasive arterial pressure monitoring for MAP during
normotensive conditions.34 However, during induction of anesthesia, and when the
arterial pressure was low, there was less agreement. Thus interchangeability between
readings was not achieved. Investigators concluded that NIBP device measures are not
statistically equivalent to invasive monitoring during all periods of anesthesia, but they
may be a useful additional arterial pressure monitor.34
Since the amplitude of the oscillations depends on several factors other than BP,
and oscillometric measurement is not continuous, in some patient conditions,
measurements were found to be inaccurate when compared to gold-standard intra-arterial
monitoring. For example, MAP may be significantly underestimated41,43 in patients with
stiff, atherosclerotic arteries and wide pulse pressures. Additionally, in patients with
dysrhythmias, such as atrial fibrillation, oscillometric device measurements were found to
be unreliable.28 When the cuff is inﬂated, and the artery is partially or fully occluded,
pressure oscillations created by the expansion of the arterial wall during each heartbeat
are sensed by the cuff and measured by the device’s hardware and software.99 Therefore,
the irregularity in heart rate, strength, and rhythm that occur with atrial fibrillation
decrease the reliability of the displayed parameters.
Independent studies by Pagonas et al. in 2013113 and Lakhal et al. in 2015114 and
2017 , offer a differing opinion on the generalized belief that NIBP measurements are
inaccurate in patients with arrhythmias. These investigators submit that most available
studies116,117, which addresses the reliability of NIBP measurements during arrhythmia, is
misleading since the auscultatory method was used as the reference gold standard117
rather than arterial line measurement. They add that during an arrhythmia, the
auscultatory method is exposed to inter- and intra-observer bias owing to the beat-to-beat
variability of pulse pressure and thereby of Korotkoff sounds.115
115

In studies of agreement, Pagonas et al113 compared NIBP measures with intraarterial measurements in ICU or intermediate care unit patients with atrial fibrillation and
sinus rhythm. Lakhal et al.114,115 compared NIBP measures with intra-arterial
measurements in ICU patients with atrial fibrillation, atrial flutter, and frequent extra
systoles. Both Pagonas et al. and Lakhal et al. used the ANSI/AAMI/ISO validation
criteria of accuracy (mean BP difference ≤5 mm Hg) and precision (SD ≤8 mm Hg).103
In all three studies, the investigators found that arrhythmias did not significantly impact
the agreement of NIBP measures with intra-arterial measures, and did not significantly
affect the accuracy of oscillometric measurements as long as three repeated measures of
the mean are averaged.113-115
Cuff size and upper arm circumference have been found to affect the accuracy of
NIBP oscillometric devices.118,119 Using 1494 pairs of simultaneous oscillometric and
invasive arterial MAP measurements collected in 38 critically ill patients over 72 hours,
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Bur and colleagues found that use of inotropic support and the position of the cuff did not
affect the accuracy of the oscillometric method; however, the relation between cuff size
and upper-arm circumference contributed substantially to the differences between
oscillometric and invasive arterial MAP measurements. NIBP oscillometric MAP
measurement in patients who had smaller than the recommended cuff sizes resulted in
smaller discrepancies between invasive and noninvasive MAP measurement compared
with the recommended cuff sizes.118
NIBP Agreement with Manual Sphygmomanometer Measurement
Studies have also demonstrated the underestimation of BP measurement by NIBP
devices at increasing BP levels.40,43 A retrospective review of 30 studies which examined
the accuracy of BP measurement by oscillometric ambulatory devices (12 studies) and
non-ambulatory devices (18 studies) performed between 1993-2003, the accuracy of BP
measurement, particularly SBP, decreased at increasing blood pressure levels.43
Reviewers speculated whether this finding could be due to the oscillometric method of
BP measurement, or whether the decrease in accuracy could be explained by increasing
blood pressure variability at increasing blood pressure, and the use of sequential
measurements.43
With regard to SBP agreement between NIBP and manual mercury
sphygmomanometry, a study by Coe et al. found opposite results in that the NIBP device
over-read SBP by a mean of 8.38 mmHg, and under-read DBP by a mean of 1.68 mmHg,
when compared with manual readings. Although the NIBP readings were found to be
clinically reliable at normotensive values, the error increased at borderline hypertensive
levels and higher. Investigators summarized that 6.5% of the study participants would
have been inappropriately diagnosed as hypertensive from the NIBP device readings, and
thus potentially rejected from day surgery and inappropriately referred to their general
practitioner. Due to this finding, investigators conclude with a recommendation to
recheck the BP using a manual sphygmomanometer for any hypertensive reading by an
NIBP device.120
Similar findings were reported by Keavney et al.40 where NIBP measures were
less accurate than manual sphygmomanometry. The proportion of NIBP readings that
differed from the observers’ readings by 5 and 10 mmHg was higher with the
oscillometric technique than with manual sphygmomanometry. Higher SBPs were
under-estimated by the NIBP device, while lower SBPs tended to be over-estimated.
Interestingly, the crossover point occurred at approximately 150 mmHg. These trends
were not discernible for the differences between DBP measurements.40 MAP was not
addressed in this study.
Kiers et al.121 compared the MAP measured with an NIBP oscillometric device
with the MAP calculated using the SBP and DBP measured by auscultation using the
formula DBP + 1/3 Pulse Pressure. Results showed a significant difference between
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measured MAP and calculated MAP (p<0.001) and therefore, concluded that measured,
and calculated MAP cannot be used interchangeably.121
Araghi et al. 122 compared arterial blood pressure (ABP) with NIBP measurements
obtained using both auscultatory and oscillometric methods in 54 overweight critically ill
patients and concluded that NIBP in this patient population could be inaccurate.
Oscillometric BP measurements underestimated ABP readings regardless of patient body
mass index, whereas auscultatory measurements underestimated SBP and overestimated
MAP and DBP.
In a study that used two geometric models for numerical analysis, one a cylindershaped ideal model, and the other an anatomic model reconstructed from CT scan images
of an upper arm segment, researchers investigated the mechanical response of soft tissues
to cuff pressurization and found that a thickened subcutaneous fat layer in obese subjects
significantly reduced the effective pressure transmitted to the brachial artery. 123 They
postulated that this might explain why blood pressure overestimation occurs more
frequently in obese subjects in NIBP measurement.123
Despite questions of accuracy, NIBP devices have become the clinical standard,
in large because of a decrease in training requirements.99 Of the parameters displayed on
NIBP devices, patient medical management is guided mostly by SBP and DBP. It is
likely that most clinicians are not aware that the design of the devices, as well as the
preponderance of study results, support the MAP as the most accurate of the displayed
measures. Additionally, few clinicians understand the issues and procedures which may
affect the accuracy of these devices.
As technology has evolved, newer, proprietary algorithms boost improved
sensitivity to differences in pulse pressure and arterial stiffness.31 In 2012, biomedical
engineers published a paper that detailed the development of an algorithm that predicts
cuff pressure oscillations produced during NIBP oscillation measurements and allows
accurate extraction of systolic and diastolic pressures in the presence of varying arterial
stiffness or varying pulse pressure. Unlike the closely held trade secret31 of most NIBP
device proprietary algorithms, the engineers placed their algorithm in the public domain
and invited others to independently test and refine their approach.31
Best Practice for Measurement of BP by Manual Sphygmomanometry and NIBP
With both manual sphygmomanometry and NIBP devices, the most common
error in BP measurement is the use of inappropriate cuff size. Too narrow or too short a
cuff bladder (undercufﬁng) results in an overestimation of BP and too wide or too long a
bladder (overcufﬁng) results in an underestimation of BP.124 The bladder length
recommended by the American Heart Association is 80 percent of the patient’s arm
circumference, and the ideal width is at least 40 percent.125 Error is minimized when the
cuff width is 46 percent of the arm circumference. In obese patients, longer, wider cuffs
are needed to compress the brachial artery adequately. If there is uncertainty regarding
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correct cuff size, clinicians should refer to a table that details recommended cuff sizes
based on arm circumference.125
Best practice also includes placing the lower edge of the cuff 2-3 cm above the
antecubital fossa, squeezing all of the residual air out of the cuff before applying it to the
arm or leg, wrapping the cuff snugly around the arm, instructing the patient to refrain
from talking or moving, letting nothing press against the cuff during measurement, and
ensuring that the cuff and heart are at the same horizontal level.126
Additionally, a minimum of two readings should be taken, and the average of
those readings should be used to represent the patient’s BP. If there is more than 5
mmHg difference between two consecutive readings, additional readings should be
performed, and their average should be used. At least a 1-minute interval should be
adopted between the two consecutive readings.105
Manual Sphygmomanometry (Korotkoff) Technique
The Korotkoff technique requires the use of both a sphygmomanometer
(inflatable cuff with a pressure gauge) and a stethoscope to link pressure changes with the
return of blood flow. As the cuff inflates, the artery is occluded. As the cuff deflates, the
blood flow generated produces the turbulence needed to produce Korotkoff sounds. In
extremely large patients, in those with excessively calcified (and rigid) arteries,127 and in
patients with severe hypotension, this technique may fail secondary to the inability to
hear Korotkoff sounds.
The proper technique for blood pressure measurement using cuff and
sphygmomanometer is described by Pickering et al. in the AHA Scientific Statement for
Recommendations for Blood Pressure Measurement in Humans and Experimental
Animals.125 The examiner should first palpate the brachial artery in the antecubital fossa
and place the midline of the bladder of the cuff on the patient’s upper bare arm so that it
is just above the brachial arterial pulsation. To allow room for placement of the
stethoscope, the lower end of the cuff should be 2 to 3 cm above the antecubital fossa. If
the cuff touches the stethoscope, artifactual noise will be generated. The cuff is first
inflated without auscultation until the pulse is no longer apparent on palpation; this
identifies the level of suspected systolic pressure. The cuff should initially be inflated to at
least 30 mmHg above the point at which the radial pulse disappears. The rate of deflation has a
significant effect on blood pressure determination. Deflation rates >2 mm per second can lead to
a significant underestimation of systolic and overestimation of diastolic blood pressure.125 As

the cuff is gradually deflated, pulsatile blood flow is re-established and accompanied by
Korotkoff sounds, phase 1 sounds indicating SBP, and phase 5 sounds indicating DBP.
Neither the examiner nor the patient should talk during the measurement.125
The key to good measurement is the use of a high-quality stethoscope with clean
earpieces and short tubing. Inexpensive stethoscopes may lack good tonal transmission
properties required for accurate auscultatory measurement.124,125 Korotkoff sounds are
best heard using the bell of the stethoscope over the palpated brachial artery in the
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antecubital fossa. However, it probably does not matter much if the bell or diaphragm is
used in routine blood pressure measurement, provided the stethoscope is placed
accurately.124
BP measurements should initially be taken on both arms. If reproducible
differences greater than 20 mmHg for systolic or 10 mmHg for diastolic pressure are
present on consecutive readings124, the presence of a cardiovascular abnormality should
be considered. During emergency care of a patient, clinical judgment should be used
when deciding whether the difference is significant enough to warrant delay of treatment
to work-up the potential cause of the difference.
In older patients with a wide pulse pressure, the Korotkoff sounds may become
inaudible between systolic and diastolic pressure, and reappear as cuff deflation is
continued. This phenomenon is known as the auscultatory gap. In some cases, this may
occur because of fluctuations of intra-arterial pressure and is most likely to occur in
subjects with target organ damage.109 The auscultatory gap often can be eliminated by
elevating the arm overhead for 30 seconds before inflating the cuff and then bringing the
arm to the usual position to continue the measurement. This maneuver reduces the
vascular volume in the limb and improves inflow to enhance the Korotkoff sounds.125 If
a wide variation in BP measurements is recorded, clinicians should consider the
auscultatory gap and/or cardiac dysrhythmias as possible culprits.
BP examiners should be assessed for eye/hand/ear coordination, which is required
to ensure proper technique for manual sphygmomanometer BP Monitoring. They should
be able to see the dial of the manometer at eye level without straining or stretching and
see the sphygmomanometer from three feet away. Additionally, the examiner must be
able to hear the appearance and disappearance of Korotkoff sounds.
Benefits of manual sphygmomanometer BP monitoring are that the equipment is
often inexpensive, lightweight, and portable. Additionally, the gauge will function in any
position, as long as the examiner is able to view it directly. Limitations include multiple
opportunities for major sources of error, including inappropriate cuff size, incorrect
stethoscope placement, examiner error via inadequate hearing acuity or incorrect
technique, and rapid cuff deflation.
NIBP Oscillometric Technique
The physical requirements for the examiner using an NIBP oscillometric device
are much less than with a manual sphygmomanometer, so the importance of eye/hand/ear
coordination is markedly reduced. As noted earlier, initial training is required for the
selection of the correct cuff size and placement, proper patient positioning125, and
ensuring that the cuff is at heart level.
Since development for each brand of NIBP device is proprietary, examiners
should refer to the user’s manual for their specific device. As noted earlier,
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ANSI/AAMI/ISO has published validation criteria to check for the accuracy of the NIBP
device.103 In addition, the organization has published environmental standards for safety
and performance, which include maintaining ranges for temperature (10-40°C), humidity
(15-90% noncondensing), and altitude (-170 to 1,700 m referenced to sea level). For
safety, the maximum cuff pressure should never exceed 330 or 30 mmHg above the
upper limit of the instrument’s manufacturer-specified operative range, whichever is
higher. Only devices independently validated according to standard protocols should be
used, and individual calibration is recommended.103
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CHAPTER 3.

MATERIALS AND METHODS
Research Design

The purpose of this prospective observational study was to examine the
agreement of systolic blood pressure (SBP), diastolic blood pressure (DBP), and mean
arterial pressure (MAP) measurements derived from a non-invasive blood pressure
(NIBP) device with the same measurements obtained through traditional manual
auscultatory methods in acute ischemic stroke (AIS) patients treated with alteplase.
Additionally, this deductive study examined the relationship of MAP and outcomes in
AIS patients who have received intravenous alteplase. A total of seven medical centers
(three comprehensive stroke centers – two in New Jersey (NJ) and one in Tennessee
(TN); and four primary stroke centers in NJ served as the sites for this study.
Institutional Review Board (IRB) Approval
Investigators received approval from the Institutional Review Board (IRB) at the
University of Tennessee Health Science Center (UTHSC) and at Hackensack Meridian
Health (HMH), a healthcare system in New Jersey. A waiver of informed consent and a
waiver of the Health Insurance Portability and Accountability Act Authorization
(HIPAA) was granted by both IRBs. Study protocol and procedures did not interfere
with evidence-based standard of care treatment for AIS patients. Additionally, formal
data-sharing agreements between the UTHSC and HMH’s study sites were obtained.
Study Inclusion and Exclusion Criteria
Patients eligible for enrollment in the study were those who met current inclusions
without exclusions for treatment with alteplase as set forth in the 2018 Guidelines for the
Early Management of Patients with Acute Ischemic Stroke1 and the 2019 guideline
updates10 that follow:
Inclusion Criteria
•
•
•
•
•

Age >18 years old.
Diagnosis of ischemic stroke.
Onset of symptoms <4.5 hours before beginning treatment.
Baseline computed tomography scan of the brain negative for hemorrhage.
Alteplase bolus and infusion received within the previous 24 hours.

24

Exclusion Criteria
•
•
•
•
•
•
•

Significant head trauma, intracranial or spinal surgery in the previous 3 months.
Suspected subarachnoid hemorrhage.
Current intracranial hemorrhage.
Known conditions that could increase the risk for hemorrhage (i.e. intracranial
neoplasm, arteriovenous malformation, or aneurysm).
Inability to control blood pressure (systolic >185 mm Hg or diastolic >110 mm
Hg) with intravenous antihypertensive agents (i.e., labetalol bolus or nicardipine
infusion).
Active internal bleeding.
Acute bleeding diathesis, including but not limited to:
▪
▪
▪
▪

Platelet count <100 000/mm³.
Heparin received within 48 hours, resulting in abnormally elevated aPTT
greater than the upper limit of normal.
Current use of warfarin with INR >1.7 or PT >15 seconds.
Current use of direct thrombin inhibitors or direct factor Xa inhibitors with
elevated sensitive laboratory tests (such as aPTT, INR, platelet count, and
ECT; TT; or appropriate factor Xa activity assays).

Study Specific Exclusion Criteria
Our study also adopted the following exclusion criteria that go beyond what is
specified in the 2018 Guidelines and 2019 updates.1,10
•
•

•

Patients in atrial fibrillation or atrial flutter. (Oscillometric NIBP readings taken
from patients in these rhythms are difficult to interpret due to significant beat-tobeat variation in MAP.28,30)
Patients with upper arm circumference that exceeded the sizing recommendations125 for either the NIBP or manual obese cuff parameters. (NIBP device
measurements have been shown to be inaccurate in patients with ill-fitting blood
pressure cuffs.)
Patients on any form of isolation/contact precautions.
Protocol

Acute ischemic stroke patients who met inclusions without exclusions as detailed
in the 2018 Guidelines for the Early Management of Patients With Acute Ischemic
Stroke1 and the 2019 guideline updates,10 were eligible for study participation. Baseline
pre-alteplase infusion SBP, DBP, MAP, and pre-treatment National Institute for Health
Stroke Scale (NIHSS) scores were recorded, along with standard demographic variables,
stroke arterial territory, antihypertensive medications used for treatment, and the dose
prescribed, along with stroke mechanism. Medical conditions affecting the
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cardiovascular system were also recorded, along with the dose of alteplase administered.
Any additional treatment by thrombectomy was recorded along with Post-Treatment
Thrombolysis in Cerebral Infarction (TICI) recanalization scores. Patient outcome
measure after reperfusion including discharge modified Rankin Score (mRS) and the
discharge NIHSS scale5,23 were also recorded.
Two examiners simultaneously measured BP readings with the use of a dualauditory stethoscope following the technique described by Pickering, et al. in the AHA
Scientific Statement for Recommendations for Blood Pressure Measurement in Humans
and Experimental Animals 125 (refer to study process steps below). In addition, the
design of the study protocol was informed by the ANSI/AAMI/ISO protocol from their
2013 publication: Non-Invasive sphygmomanometers - Part 2: Clinical Validation of
automated measurement103 and by the AAMI/ESH/ISO 2018 Collaborative Statement: A
Universal Standard for the Validation of Blood Pressure Measuring Devices.101
Study Instruments and Supplies
The instruments and supplies used for the study, were as follows:
•
•
•
•
•
•

General Electric Brand oscillometric NIBP device with valid and current
biomedical inspection at the time of the study – supplied and used by all NJ study
sites.
Drager oscillometric NIBP device with a valid and current biomedical inspection
at the time of the study – supplied and used by TN study site.
Prestige Medical Clinical I Teaching Edition, dual auditory stethoscopes were.
purchased from Amazon and supplied to each study site.
Disposable WIN TAPE 1 Meter 40" Paper Tape Measures for measurement of
each patients’ arm circumference were purchased from Amazon and supplied to
each study site.
Standard blood pressure cuffs (small/child, average, and large) supplied by each
hospital study site.
Hospital approved cleaning agent for reusable blood pressure cuffs supplied by
each study site.
Study Process Steps

Blood Pressure Measurements
Two trained examiners measured five sets of manual-derived BP and NIBPderived SBP, DBP, and MAP in acute ischemic stroke patients treated with alteplase. For
the manual measures, the two examiners used a dual-auditory stethoscope to ensure
accuracy of the measurement. The manual measurement was followed within 5-10
minutes by the NIBP measurement. To avoid interruption of acute stroke care, all
measurements occurred during the 24 hours following the alteplase infusion. There was
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no specific time during the 24 hours for the 5 sets of paired measurements to be
completed.
The patient’s arm circumference was measured with the disposable paper
measuring tape, which was provided to each study site by the investigators. All seven
study sites used the same brand of measuring tape. Appropriate BP cuff size was guided
by Recommended Cuff Sizes for Accurate Measurement of Blood Pressure5 (Table 3-1).
Manual Blood Pressure Measurement
1. With the use of a dual-auditory stethoscope, two examiners, referred to as
Examiner 1 and Examiner 2, first took a manual BP measurement, followed
within 5-10 minutes by an NIBP measurement
2. Prior to initiation of manually derived blood pressure measurements, Examiner 1
explained to the patient the purpose of the set of blood pressure measurements
with the dual-auditory stethoscope and the NIBP device using the following IRBapproved script:
The two of us are taking your blood pressure with a stethoscope that has
2 sets of ears. With this type of stethoscope, both of us can listen to your
blood pressure at the same time to make sure we both hear the same blood
pressure. We will write your blood pressure down on this form
(Examiner will show the Case Report Form).
We will then take your blood pressure with this blood pressure machine
and write your blood pressure from the machine on the form as well. We
will use these numbers in a study to find out whether the blood pressures
we hear with the stethoscope matches the blood pressure from the machine.
We also want to understand what the third number on the blood pressure
machine means in relation to the top and bottom blood pressure numbers.
(Examiner will point to the MAP on the NIBP device). (Note: Examiner
may say “systolic and diastolic” if the patient understands what these words
mean.)
3. The Examiners followed the technique described by Pickering et al. in the
American Heart Association’s Scientific Statement for Recommendations for
Blood Pressure Measurement in Humans and Experimental Animals.125 The
technique is further described in Step 5 of the Technique for Manual BP
Measurement below. This technique was modified only for two examiners
utilizing a dual-auditory stethoscope.
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Table 3-1.

Recommended cuff sizes for accurate measurement of blood pressure.

Adult Arm Size Circumference
22 to 26 cm

Recommended Cuff Size (cm)
12 x 22 cm (small adult)

27 to 34 cm

16 x 30 cm (adult)

35 to 44 cm

16 x 36 cm (large adult)

Data Source: Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood
pressure measurement in humans and experimental animals: part 1: blood pressure
measurement in humans: a statement for professionals from the Subcommittee of
Professional and Public Education of the American Heart Association Council on High
Blood Pressure Research. Circulation. 2005;111.
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Non-invasive Blood Pressure (NIBP) Measurement
NIBP measurements are a routine part of the standard of care treatment for acute
ischemic stroke patients.
1. Both manual BP and NIBP measurements were taken from the same arm. After
the Examiners recorded the SBP and DBP manual measurements, the manual cuff
was removed, and the appropriate-sized NIBP device cuff was placed using
standard of care technique.
2. Each of the two measurement-methods were taken within 5-10 minutes of each
other to allow time for the patient’s arm to fully revascularize and relax between
measurements; otherwise, the data from the NIBP device would likely have been
erroneous.
Additional Information Regarding Manual BP and NIBP Device Measurement
1. To avoid potential bias from NIBP device BP measurement results, the manual
BP was always taken before the NIBP measurement.
2. The manual BP and NIBP taken as part of the study protocol did not guide patient
treatment.
3. The clinician guiding the AIS patient’s treatment was permitted to ask for the
study BPs from the Examiners at any time.
4. If the clinician decided to use a study BP measurement to guide treatment, rather
than the BP obtained as normal standard of care, from that point on, the patient
would be excluded from the study. As this was an observational study only, this
stipulation ensured that no treatments were based on measures obtained as part of
the study protocol.
(Note: There was no instance of this occurring during the study period.)
Technique for Manual BP Measurement
Examiner 1 and Examiner 2 listened for the SBP and DBP using a dual-auditory
stethoscope. All examiners were health care providers, i.e., Registered Nurses (RNs),
Advanced Practice Nurses (APNs), and/or Physicians (MDs or DOs) trained and
experienced in taking manual BPs from the technique described in the American Heart
Association’s Scientific Statement for Recommendations for Blood Pressure
Measurement in Humans and Experimental Animals.125 This technique was modified
only in regard to two examiners utilizing a dual-auditory stethoscope.
1. Examiner 1 palpated the brachial artery in the antecubital fossa and placed the
midline of the bladder of the cuff on the patient’s upper bare arm so that it is just
above the brachial arterial pulsation. To allow room for placement of the
stethoscope, the lower end of the cuff was positioned 2 to 3 cm above the
antecubital fossa.
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2. Examiner 1 first identified the level of the suspected SBP by palpating the
patient’s pulse at the brachial or radial artery while inflating the cuff without
auscultation. The level where the pulse is no longer palpable is the suspected
SBP.
3. Both Examiner 1 and Examiner 2 prepared to listen for the BP measurement by
placing their respective ends of the dual auditory stethescope in their ears.
4. Examiner 1 placed the stethoscope over the brachial artery. To avoid artifactual
noise, both examiners ensured that the stethoscope did not touch the cuff.
5. Examiner 1, who initially determined the level of the SBP, inflated the cuff to at
least 30 mmHg above the point at which the radial pulse was determined to
disappear.
6. To avoid significant underestimation of systolic and overestimation of DBP,
Examiner 1 deflated the cuff at a rate of <2 mm per second.
7. As the cuff was gradually deflated and pulsatile blood flow re-established, both
examiners listened for the appearance of Korotkoff sounds. Phase 1 Korotkoff
sound is characterized by a clear, repetitive tapping sound, coinciding with the
reappearance of a palpable pulse.128 The initial appearance of phase 1 sounds is
equal to the SBP. The point at which the repetitive tapping disappears is
considered to be the phase 5 Korotkoff sound, which indicates the DBP.
8. Neither the examiners nor the patient should talk during the measurement.125
Valid and Invalid Blood Pressure Measurements
1. Examiner 1 and Examiner 2 reported to each other the SBP and DBP they heard.
For this study, a “valid BP measurement” was achieved when less than a 4 mmHg
difference between the SBP and DBP between the Examiners’ measures was
reported. The SBP and DBP heard by Examiner 1 was the measurement used for
the study, and thus was recorded on the CRF. However, if a difference of more
than 4 mmHg existed between either the SBP or DBP from Examiner 1 and
Examiner 2’s reported measurements, then the BP measurement was considered
“invalid”.
2. In cases where “invalid BP measurements” were found, the Examiners waited at
least five minutes before repeating another “set” of blood pressure measurements.
3. This process was repeated until a total of 5 “valid” sets of manual and NIBP
measurements were recorded within 24 hours of the patient receiving the alteplase
bolus and infusion. There were no set times in which the measurements must be
taken; however, they must all have occurred within 24 hours after the patient
received alteplase.
Data Collection
Patient enrollment and data collection took place over 13 months. Study sitespecific investigators ensured inclusion and exclusion criteria were satisfied before
enrolling an AIS patient in the study. Patient study variables were recorded on a case
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report form (Appendix B) then de-identified and transferred to a research database
maintained in an Excel spreadsheet. A unique identifier was assigned to each study
patient by the principal investigator.
Data Analysis
Data from five sets of manual-derived BP and NIBP-derived measures for SBP,
DBP, and MAP were collected from 95 patients from seven hospitals: six hospitals based
in NJ, and one hospital in TN. Data was exported from an Excel research database to
IBM SPSS Statistics 22.0 for descriptive analysis, tests of significance (parametric and
non-parametric t-test), and normality analysis. NCSS Statistical Software (2020) was
used for Bland-Altman analysis for measures of agreement and Lin’s concordance
correlation coefficients were used to analyze agreement between the paired readings.

31

CHAPTER 4.

RESULTS

Between February 2019 and February 2020, seven medical centers (two
comprehensive stroke centers in New Jersey [NJ], one comprehensive stroke center in
Tennessee [TN], and four primary stroke centers in NJ) enrolled alteplase-treated AIS
patients in this prospective, observational study. Our study population consisted of 95
AIS patients: 62 from NJ and 33 from TN, with mean age 69; 61% men, and 76% with a
history of hypertension (Table 4-1).
Bland-Altman Analysis for Measures of Agreement
To test for agreement between the manual and NIBP measures, analyses were run
using the Bland-Altman (BA) analysis for measures of agreement.129-132 The BA analysis
is a technique used to compare two measurements of the same variable. The question to
be answered is whether the two methods of BP measurement are comparable to the extent
that one might replace the other with sufficient accuracy for the intended purpose of BP
measurement.129 The analysis incorporates the Bland-Altman (BA) scatter plot,
descriptive statistics, test of normality, significance of bias, and limits of agreement, and
assumption plots.
Bland and Altman’s technique for measuring agreement was first introduced in
1983. Since that time, the method has evolved, with the authors, in a series of articles
published between 1983-2007 further refining, clarifying, and defining alternate and
additional techniques researchers may consider based on the type and quantity of the data
collected, and the method of data collection.
What follows are BA statistical tests for the analysis of measures of agreement for
475 sets of manual BP and NIBP-derived SBP, DBP, and MAP from 95 patients. The
differences between SBP, DBP, and MAP measurements, and prediction limits for the
difference between pairs of future measurements, known as the limits of agreement are
shown.133 For this analysis, each of the 475 sets of measures were treated independently.
The Bland-Altman Scatter Plot
In their introductory article; “Measurement in Medicine: The Analysis of Method
Comparison Studies,”130 Altman and Bland state that the mandatory first step for method
comparison studies is to plot the data. As an integral part of the analysis, this visual tool
is often simply referred to as a Bland-Altman Plot (BA plot). The BA plot is essentially a
standard scatter plot with the addition of limits of agreement (LoA) and a difference
(bias) line. It consists of a plot of the difference between paired readings of two variables
(i.e. manual BP measures and NIBP device measures) over the average of these readings,
with 2 standard deviation (SD) lines (confidence interval [CI]) parallel to the mean
difference line.134
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Table 4-1.

Demographic/Baseline characteristics of the study population.

Variables
Age, mean (SD)

All Study
Sites
(n = 95)

TN Values
(n = 33)

NJ Values
(n = 62)

69 (14)

65 (12.3)

71 (14.6)

Gender

p-Value
(t-test, chisquare, and
median test)
<0.05*(0.04)
p = ns (0.41)

Male, n (%)

58 (61)

22 (67)

36 (58)

Female, n (%)

37 (39)

11 (33)

26 (42)

Ethnicity
Caucasian, n (%)
African American, n (%)
Hispanic, n (%)

<0.05**(0.000)
61 (64)
30 (32)
4 (4)

9 (27)
23 (70)
1 (3)

52 (84)
7 (11)
3 (5)

Hypertension, n (%)

72 (76)

24 (73)

48 (77)

p = ns (0.61)

Diabetes mellitus, n (%)

33 (35)

14 (42)

19 (31)

p = ns (0.25)

HgbA1c, mean (SD)

6.4 (1.6)

6.5 (1.8)

6.3 (1.4)

p = ns (0.58)

Smoking, n (%)

30 (32)

11 (33)

19 (31)

p = ns (0.79)

Previous Stroke, n (%)

25 (27)

13 (41)

12 (19)

<0.05* (0.03)

Baseline NIHSS, Median (Q1, Q3)

5 (3, 11)

5 (3, 7)

6 (3.25, 13)

<0.05* (0.04)

Pre-Stroke Modified Rankin Score,
Median (Q1, Q3)

0 (0, 1)

0 (0, 2)

0 (0, 1)

p = ns (0.99)

Notes: p = ns refers to non-significant; p-value*<0.05; p-value**<0.001. For categorical
variables (gender, ethnicity, HTN, DM, smoking, previous stroke) chi-square test was
used. For continuous variables (age, A1C), a student’s t-test was used. For baseline
NIHSS and baseline mRS, non-parametric median test for difference in the medians.
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The difference in the readings from the two methods, manual BP and NIBP
measurements, are plotted on the y-axis, and the average of the readings from the two
methods are plotted on the x-axis. The data cluster around a regression line by definition
regardless of the agreement.129 The BA plot’s visual format makes it easier to assess the
magnitude of disagreement, spot outliers, and determine if a trend exists in the data. It
displays four types of data misbehavior: (1) systematic error (mean offset), (2)
proportional error (trend), (3) inconsistent variability, and (4) excessive or erratic
variability.134
To make a determination that no remarkable data misbehavior is present, the
measurement points should center about difference = 0, provide a reasonable confidence
interval, and remain in the same general pattern for all horizontal axis values.134 Only
about 5% of the data should lie outside the plus-minus CI, and these points should not be
dramatically far outside the confidence interval. If too many points lie outside, then the
data are erratically variable.134
Descriptive Statistics
Descriptive statistics of the count, mean, standard deviation (SD) and 95% CI,
bias, and LoA for manual and NIBP measured SBP, DBP, and MAP were generated for
our measurement data.
Test of Normality of Differences
To test for normality of the distribution of the variables and to test the statistical
significance of the bias, the Shapiro Wilk parametric test was used.
Assumptions Plots
A histogram, normal probability plot of difference, and a linear scatter plot) were
generated to show the behavior of the data from the manual measures in relation to NIBP
measures. These plots facilitate visual assessment for whether a data set is approximately
normally distributed.
Lin’s Concordance Correlation Coefficients (CCC)
Lin’s CCC were also computed to provide a further understanding of the data’s
behavior. CCCs are used to evaluate the agreement between paired readings when the
variable of interest is continuous.135,136 Values near +1 indicate strong concordance
between x and y; values near -1 indicate strong discordance, and values near zero indicate
no concordance.137 However, researchers have various interpretations. Altman interprets
the correlation with <.20 as poor and >.80 as excellent,138,139 whereas McBride suggests
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the following interpretation: <0.90: poor; 0.90 to 0.95: moderate; 0.95 to 0.99:
substantial; and >0.99 almost perfect.139,140
Additional Tests
In addition to the BA analyses, parametric tests, non-parametric tests, and further
descriptive statistics were run for additional data comparison.
Systolic Blood Pressure
Bland-Altman Scatter Plot for SBP
The Bland-Altman scatter plot for SBP (Figure 4-1) illustrates the difference
between the two methods (manual minus NIBP) against the average of the two methods
(manual plus NIBP)/2. The figure shows the center dotted line (y = 0) and the line of
bias (mean difference). Here, the bias is the mean difference and is equal to -3.75 points
or mmHg. This indicates the average NIBP device readings were higher than the manual
readings. The lower control limit (LCL) (mean – 1.96*SD) and upper control limit
(UCL) (mean + 1.96*SD) lines show the limits of agreement (LoA). The points that lie
out of the LoA lines are outliers.
Descriptive Statistics, Bias, and Limits of Agreement for SBP
Table 4-2 shows the count, mean, standard deviation (SD), and 95% CI of the
difference for SBP measured by the two methods. The mean (SD) for manual SBP was
138(21) mmHg, and mean (SD) for NIBP SBP was 142(22) mmHg. The mean (SD) of
the bias (difference) between the two methods was -3.75 (12.8) mmHg. The NIBP
measure was subtracted from the manual BP measure. The negative result indicates that
the NIBP SBP readings were higher than manual SBP measures. The value for LCL was
-28.9 and UCL was 21.4. Note the width of the confidence interval of 50.3 mmHg
between the LCL and UCL.
Test of Normality for SBP
The Shapiro–Wilk test for normality of the difference between the two methods of
SBP measurements (manual SBP minus NIBP SBP) yielded a value of 0.990 (p=0.0025);
thus, the hypothesis of normality is rejected.
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Figure 4-1. Bland–Altman plot of the 475 manual SBP versus NIBP SBP
measures.
The dotted line indicates difference of manual minus NIBP SBP (y-axis) = 0, the line of
perfect average agreement. The red line is the line of bias (the actual difference of
manual minus NIBP SBP). a) The points center about the difference = 0 and are in the
same general pattern for all horizontal axis values. b) The mean is offset, lying below
zero, suggesting a mean bias (a systematic error). c) 2.1 percent (~10 of 475) of the data
points lie above and below the confidence limits. d) Most of the outliers fall beyond an
average reading of approx. 130 mmHg SBP.

Table 4-2.

Descriptive statistics for SBP.

Variables
MAP Manual
MAP NIBP
Difference
Lower LoA
Upper LoA

Descriptive Statistics
Count
Mean
SD
475
138.1
20.9
475
141.9
21.7
475
12.8
- 3.75
475
-28.91
1.0
475
21.41
1.0

95% CI of the Difference
Lower
Upper
136.3
140
139.9
143.8
-4.91
-2.59
-30.9
-26.9
19.41
23.39

Notes: Based on 475 sets of measures from 95 patients. LoA = Limits of Agreement and
CI = Confidence Intervals.
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Assumption Plots for SBP
Figure 4-2 shows the histogram, the normal probability plot of difference, and the
linear scatter plot for SBP measurements. These plots clearly show that the data is
skewed, not normally distributed, and there exists a large difference in the SBP manual
and NIBP measures.
Lin’s CCC for SBP
CCC was 0.82.
Diastolic Blood Pressure
Bland-Altman Scatter Plot for DBP
The Bland-Altman Scatter Plot (Figure 4-3) for DBP illustrates the difference
between the two methods (manual minus NIBP) against the average of the two methods
(manual plus NIBP)/2. The figure shows the center dotted line (y = 0) and the line of
bias (mean difference). Here, the bias is the mean difference and is equal to -1.06 points
or mmHg. This indicates the average NIBP device readings were higher than the manual
readings. The LCL and UCL lines show the LoA. The points that lie out of the limits of
agreement lines are outliers.
Descriptive Statistics, Bias, and Limits of Agreement for DBP
Table 4-3 shows the count, mean, standard deviation (SD), and 95% CI of the
difference for DBP measured by the two methods. The mean (SD) for manual DBP was
73(12) mm/Hg, and mean(SD) for NIBP DBP was 74(13) mm/Hg. The mean (SD) of the
bias (difference) between the two methods was -1.06(10.2) mmHg. The NIBP measure
was subtracted from the manual measure. The negative result indicates that the NIBP
DBP readings were higher than manual DBP measures. The value for LCL was -21.0,
and UCL was 19.0. Note the width of the confidence interval of 40.0 mmHg between the
LCL and UCL.
Test of Normality for DBP
The Shapiro–Wilk test for normality of the difference between the two methods of
DBP measurements (manual DBP minus NIBP DBP) yielded a value of 0.993 (p =
0.0273); thus, the hypothesis of normality is rejected.
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Figure 4-2. Assumption plots for normality (histogram, normal probability plot,
and linear plot) for SBP.
a) The histogram is skewed left and thus is not normally distributed. b) The normal
probability plot of the difference shows longer than expected tails with the data points
skewed from the extremes, indicating the distribution of the data was not normal. c) The
linear scatter plot where manual and NIBP readings are plotted against each other on an x
and y-axis (centerline is the y = x line). Data points are deviating (scattered) from the
centerline of equality and are widely dispersed, indicating that the linear relationship is
not strong. The points that are away from the centerline indicate that there is a difference
in the manual and NIBP readings. The drawn line connecting one point to the y-axis and
the x-axis illustrates that there is a difference in the manual and NIBP readings. Here, the
SBP NIBP (y-axis) is approximately 165, and the manual SBP (x-axis) is approximately
135.
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Figure 4-3. Bland–Altman plot of the 475 manual DBP versus NIBP DBP
measures.
The dotted line indicates difference of manual minus NIBP DBP (y-axis) = 0, the line of
perfect average agreement. The red line is the line of bias (the actual difference of
manual minus NIBP DBP). a) The points center about the difference = 0 and are in the
same general pattern for all horizontal axis values. b) The mean is offset, lying below
zero, suggesting a mean bias (a systematic error). c) 3.4 percent (~16 of 475) of the data
points lies above and below the confidence limits. d) Most of the outliers fall below an
average reading of 80 mmHg DBP.

Table 4-3.

Descriptive statistics for DBP.

Variables
DBP Manual
DBP NIBP
Difference
Lower LoA
Upper LoA

Descriptive Statistics
Count
Mean
SD
475
73.2
12.4
475
74.3
13.4
475
10.2
-1.06
475
-21.0
0.80
475
19.0
0.80

95% CI of the Difference
Lower
Upper
72.1
74.3
73.0
75.5
-1.98
0.14
22.6
-19.5
17.3
20.5

Notes: Based on 475 sets of measures from 95 patients. LoA = Limits of Agreement and
CI = Confidence Intervals.
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Assumption Plots for DBP
Figure 4-4 shows the histogram, the normal probability plot of difference, and the
linear scatter plot for DBP measurements. These plots clearly show that the data is
skewed, not normally distributed, and there exists a large difference in the DBP manual
and NIBP measures.
Lin’s CCC for DBP
CCC was 0.69.
Mean Arterial Pressure
Bland-Altman Scatter Plot for MAP
The Bland-Altman scatter plot (Figure 4-5) for MAP illustrates the difference
between the two methods (manual minus NIBP) against the average of the two methods
(manual plus NIBP)/2. The figure shows the center dotted line (y = 0) and the line of
bias (mean difference). Here, the bias is the mean difference and is equal to -5.49 points
or mmHg. This indicates the average NIBP device readings were higher than the manual
readings. The LCL and UCL lines show the LoA. The points that lie out of the LoA lines
are outliers.
Descriptive Statistics, Bias, and Limits of Agreement for MAP
Table 4-4 shows the count, mean, standard deviation (SD), and 95% CI of the
difference for MAP measured by the two methods. The mean (SD) for manual MAP was
95(13) mm/Hg, and mean (SD) for NIBP MAP was 100(17) mmHg. The mean (SD) of
the bias (difference) between the two methods was -5.49(11) mmHg. The NIBP measure
was subtracted from the manual measure. The negative result indicates that the NIBP
MAP readings were higher than manual DBP measures. The value for LCL was -27.5,
and UCL was 16.5. Note the width of the confidence interval of 44 mmHg between the
LCL and UCL.
Test of Normality for MAP
The Shapiro–Wilk test for normality of the difference between the two methods of
MAP measurements (manual MAP minus NIBP MAP) yielded a value of 0.992
(p=0.0105); thus, the hypothesis of normality is rejected.
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Figure 4-4.
Assumption plots for normality (histogram, normal probability plot,
and linear plot) for DBP.
a) The histogram is skewed left and thus is not normally distributed. b) The normal
probability plot of the difference shows that the data points are skewed, meaning the
distribution was not normal. c) The linear scatter plot where manual and NIBP readings
are plotted against each other on an x and y-axis (centerline is the y = x line). Data points
are deviating (scattered) from the centerline of equality and are widely dispersed,
indicating that the linear relationship is not strong. The drawn line connecting one point
to the y-axis, and the x-axis illustrates that there is a difference in the manual and NIBP
readings. Here, the DBP NIBP (y-axis) is approximately 105 and the manual DBP (xaxis) is approximately 62.
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Figure 4-5
Bland–Altman plot of the 475 manual MAP versus NIBP MAP
measures.
The dotted line indicates difference of manual minus NIBP MAP (y-axis) = 0, the line of
perfect average agreement. The red line is the line of bias (the actual difference of
manual minus NIBP MAP). a) The points center about the difference = 0. b) There is a
negative linear association between the difference and the average. c) A trend or error
proportional to the size of measure is seen (cluster of points moves to below the median
line as the mean MAP increases). d) The mean is offset, lying below zero, suggesting a
mean bias (a systematic error). e) 4.7 percent (~22 of 475) of the data points lie above
and below the confidence limits. Since nearly 5% lie outside the plus-minus CI, this
suggests a skew in the data and variability. f) Most of the outliers (14 of 22) fall below
the average MAP reading of 124 mmHg.

Table 4-4.

Descriptive statistics for MAP.

Variables
MAP Manual
MAP NIBP
Difference
Lower LoA
Upper LoA

Descriptive Statistics
Count
Mean
SD
475
94.8
13.4
475
100.3
17.2
475
11.2
-5.49
475
-27.5
0.9
475
16.5
0.9

95% CI of the Difference
Lower
Upper
93.6
96.0
98.8
101.9
-6.50
-4.48
-29.2
-25.8
14.8
18.2

Notes: Based on 475 sets of measures from 95 patients. LoA = Limits of Agreement and
CI = Confidence Intervals.
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Assumption Plots for DBP
Figure 4-6 shows the histogram, the normal probability plot of difference, and the
linear scatter plot for MAP measurements. These plots clearly show that the data is
skewed, not normally distributed, and there exists a large difference in the MAP manual
and NIBP measures.
Lin’s CCC for MAP
CCC was 0.76.
Non-Parametric and Parametric Findings
Since the difference between the two SBP, DBP, and MAP measurements did not
follow a normal distribution, additional testing of the significance of bias using both nonparametric and parametric student’s t-test was performed
Non-Parametric: One-Sample Wilcoxon Signed Rank Test
As the normality assumptions for 475 sets of measures for all SBP, DBP, and
MAP were rejected, the non-parametric One-Sample Wilcoxon Signed Rank Test was
used to determine if the bias (difference) in the median of the measures (null hypothesis:
median test value = 0) was significant. All three null hypotheses were rejected for SBP
p =.000, for DBP p =.049, and for MAP p =.000.
Parametric: One Sample Student’s t-Test
As the sample size was adequate, the parametric one-sample student’s t-test was
used to determine if the bias (difference) in the mean of the measures (null hypothesis:
mean test value = 0) was significant for 475 sets of measures for all SBP, DBP, and
MAP. All three null hypotheses were rejected: SBP (p = .000), DBP (p = .024), and
MAP (p = .000).
Other Findings
Each of the 475 paired sets of measures (manual and NIBP) were further analyzed
to determine how far each of the SBP, DBP, and MAP measurements fell from each
other. The differences of these measurements are presented in percentage terms.
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Figure 4-6. Assumption plots for normality (histogram, normal probability plot,
and linear plot) for MAP.
a) The histogram is skewed left and thus is not normally distributed. B) The Normal
Probability Plot of the Difference shows that the data points are dispersed at both
extremes indicating the distribution was not normal. c) The Linear Plot: manual and
NIBP readings plotted against each other on an x and y-axis (centerline is the y = x line).
Data points are deviating from the line of equality. The points that are away from the
centerline show the difference in the readings as measured by the 2 methods. The drawn
line connecting one point to the y-axis and the x-axis illustrates that there is a difference
in the manual and NIBP readings. (Here, the MAP NIBP (y-axis) is approximately 150,
and the manual MAP (x-axis) is approximately 112.
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Percent Difference in mmHg Between Manual and NIBP Device
Table 4-5 shows the percentage of measurements that fell within a difference of
5, 10, 15 and 20 mmHg for SBP, DBP and MAP separately. Eighty percent of measures
should fall within 5 mmHg and 95% should fall within 10 mmHg for clinical agreement
to be considered acceptable.141 Thus, values with a width greater than 10 mmHg (+/- 5
mmHg) are considered clinically different.
For SBP, 39% of the 475 sets of measures fell within 5 mmHg and 62% fell
within 10 mmHg. For DBP, 44% fell within 5mmHg and 72% fell within 10 mmHg. For
MAP, 34% fell within 5 mmHg and 62% fell within 10 mmHg.
Other SBP Findings
As explained earlier in chapter 1, for patients who present with AIS, the
acceptable limits for the parameters of SBP for initiation of alteplase bolus are <185
mmHg, and <180 mmHg for alteplase infusion. In the chapter, these SBP parameters
were referred to as “in bounds” and “out of bounds” for alteplase treatment. Having this
in mind, each of the 475 paired SBP measures were further analyzed to determine the
number of manual and NIBP measurements that fell within the in-bounds and out-ofbounds SBP limits for initiation of alteplase. Table 4-6 shows that in 11 instances,
manual SBP was >180 mmHg, compared to 22 instances when NIBP SBP was >180
mmHg.
Other DBP Findings
For patients who present with acute ischemic stroke, DBP “in-bounds” and “outof-bounds” limits for initiation of alteplase bolus are <110 mmHg, and for alteplase
infusion <105 mmHg. Having this in mind, each of the 475 paired DBP measures were
further analyzed to determine the number of manual and NIBP measurements that fell
within the in-bounds and out-of-bounds DBP limits for initiation of alteplase treatment.
Table 4-7 shows that in no instances did manual DBP identify values <105 mmHg
compared to six when NIBP DBP was >105 mmHg.
Other MAP Findings
Chapter 1 includes a discussion introducing MAP as a parameter to guide AIS
treatment potentially. Chapter 2 provides evidence that MAP is the value most closely
associated with NIBP accuracy. Applying the SBP and DBP out-of-bounds values (>180
and >105 mmHg, respectively) for initiation of alteplase infusion into the calculated
MAP equation produces an in-bounds MAP <130 and out-of-bounds MAP >130 mm Hg.
Having this in mind, each of the 475 paired MAP measures were further analyzed to
determine the number of manual and NIBP measurements that fell within the in-bounds
and out-of-bounds MAP limits for initiation of alteplase treatment. Table 4-8 shows in
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Table 4-5.
Variable
(n = 475)
SBP
DBP
MAP

Table 4-6.

Percent difference in mmHg between manual and NIBP device.
+/≤5 mmHg
39%
44%
34%

+/≤10 mmHg
62%
72%
62%

+/≤15 mmHg
76%
86%
78%

+/≤20 mmHg
86%
95%
89%

Mean +/SD of the Difference
(mmHg)
-3.75 + 12.84
-1.06 + 10.28
-5.49 + 11.22

The number of SBP measures <180 and ≥180 mmHg.
SBP (mmHg)
<180
≥180

Manual
463
11

NIBP
453
22

Note: SBP for each of 475 measurements from 95 patients. All measurements were
taken during the 24-hours after alteplase infusion.

Table 4-7.

The number of DBP measures <105 and ≥105 mmHg.
DBP (mmHg)
<105
≥105

Manual
475
0

NIBP
469
6

Note: DBP for each of 475 measurements from 95 patients. All measurements were
taken during the 24-hours after alteplase infusion.

Table 4-8.

The number of MAP measures <130 and ≥130.
MAP Range (mmHg)
<130
≥130

Manual
471
2

NIBP
442
30

Note: MAP for each of 475 measurements from 95 patients. All measurements were
taken during the 24-hours after alteplase infusion.
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two instances that manual MAP was ≥130 mmHg compared to 30 instances when NIBP
MAP was ≥130 mmHg.
Secondary Study Aim Results for MAP and Outcomes
Following are our results from investigating the relationship between MAP and
outcomes in alteplase-treated AIS patients
Ultimately the data were insufficient to analyze this study aim adequately. Like
current reported statistics, only 3% of our study population (3 patients) developed
symptomatic intracranial hemorrhage (sICH). Of the 95 patients, three patients died
before hospital discharge, one of which was attributed to post-alteplase sICH. Overall,
for the entire sample, the median NIHSS at admission was 5, and at discharge or day 7,
median NIHSS was 1 (Table 4-9). The baseline median modified Rankin score (mRS)
before stroke onset was 0 for the sample. Median mRS at discharge or day 7 for those
without sICH was 1; for 3 patients with sICH, median mRS at discharge or day 7 it was 5
(p = ns). Of the 3 sICH patients, 1 died before hospital discharge.
A total of 90 patients had mRS documented at hospital discharge or day 7. These
patients were dichotomized into groups based on achievement of an mRS of <2
indicating favorable outcome at the time of hospital discharge vs. those with mRS >2
indicating poor functional outcome. Manual and NIBP-derived SBP, DBP, and MAP
were analyzed for differences based on hospital discharge functional outcome (Table
4-10).

47

Table 4-9.
Outcomes for median NIHSS at baseline and 24 hours, and median
mRS at pre-stroke and discharge or day 7.
NIHSS - Baseline
5 (3, 11)

NIHSS -24-hr
2 (0, 6.25)

mRS - Pre-stroke Score
0 (0, 1)

mRS - Discharge or Day 7
1 (0, 4)

Notes: NIHSS = National Institutes of Health Stroke Scale; mRS = modified Rankin
Score. Results for median (Q1, Q3)

Table 4-10. Comparison of manual and NIBP for SBP, DBP, and MAP between
patients with favorable outcomes and poor outcomes at discharge or day 7.
Favorable Outcomes (mRS ≤2)
at Discharge or Day 7

Poor Outcomes (mRS >2)
at Discharge or Day 7

Manual SBP
Manual DBP
Manual MAP

136
73.6
94.4

141.8
72.6
95.7

p-Value
(Independent
Samples t-Test)
<0.05*(0.004)
p = ns (0.45)
p = ns (0.30)

NIBP SBP
NIBP DBP
NIBP MAP

139.7
75
100.2

145.3
73.6
100.8

<0.05*(0.008)
p = ns (0.29)
p = ns (0.74)

Means

Notes: mRS = modified Rankin Score. Favorable outcomes include 56 patients; 280
observations. Poor outcomes were patients who developed sICH and/or in-hospital death
before discharge. Poor outcomes include 34 patients with 170 observations. Discharge
mRS was not documented in the medical record for 5 patients – thus could only run
analysis on 90 patients, not 95.
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CHAPTER 5.

DISCUSSION AND CONCLUSIONS

Our study found no agreement in SBP, DBP, and MAP for 475 paired manual and
NIBP measurements, with MAP manual and NIBP measures showing the least agreement
between methods. Although DBP paired measures did not agree, they were in closer
agreement than SBP and MAP measures using Bland-Altman (BA) analysis, and 44% of
DBP measures fell within 5 mmHg of each other. Importantly, our results show that
NIBP measures were consistently higher than manual measurements and differed from
manual measurements as much as 50 mmHg for SBP, 40 mmHg for DBP, and 44 mmHg
for MAP.
Understanding Agreement
When the two methods for measuring blood pressure are compared, neither
provides an unequivocally correct measurement, so testing is performed to assess the
degree of agreement.130 Additional considerations (beyond closeness of the numerical
readings) include whether the two measurement methods produce the same mean,
whether there is any relative bias (differences), and whether variability (SD) between the
measurement methods exists.129 Even with all this in place, clinically acceptable limits of
agreement for SBP, DBP, and MAP in AIS patients must be defined a priori in order to
understand if the two measures adequately agree in the specific patient population
undergoing testing.
Determination of Acceptable Limits of Agreement
As noted above, a vital first step is to determine the acceptable bias (acceptable
limits of agreement [LoA] between measurement methods. The LoA estimates the
interval within which a proportion of the differences between measurements lie.
The LoA includes both systematic (bias) and random error (precision) and provides a
useful measure for comparing the likely differences between individual BP results
measured by manual and NIBP methods.142 For example, if we had determined that an
acceptable bias between the manual and NIBP measures was 5 mmHg, then the bias
would have been tested for the test value of 5. Since stroke guidelines are silent
regarding an acceptable bias in the AIS patient population, we tested whether significant
bias was present compared to the test value of zero. In other words, part of the
determination of agreement was based on how far from zero the mean difference of the
NIBP test method fell from the reference method, manual BP (i.e., mean manual BP
minus mean NIBP).
The BA analysis only defines the intervals of agreement; it does not determine
whether those limits are acceptable (or not) from a clinical standpoint. In other words,
how far apart measurements can be to maintain their acceptability in clinical use is a
question of judgment that must be considered by the investigators.130 We suggest that
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clinically acceptable LoA for SBP, DBP, and MAP in AIS patients should be defined a
priori in all vascular diseases based on clinical necessity, biological considerations, and
treatment goals.143 Our findings highlight the need for guideline-specified clinically
acceptable LoA between manual and NIBP measures, particularly since NIBP is almost
exclusively used today, yet, the BP goals for treatment with alteplase were originally
established to support BP measurement by manual cuff.
Many Factors Affect the Agreement Decision
In our study, the Shapiro-Wilks test was used first to test the normality of the
distribution of the SBP, DBP, and MAP, and normality was rejected for all 3 BP
parameters (p<0.05). The non-parametric one-sample Wilcoxon signed rank test was
used to determine the significance of the difference using the null hypothesis for each of
the BP parameters; median test value = 0. All three null hypotheses were rejected for the
difference in SBP, DBP, and MAP measures. The parametric one-sample student’s t-test
was used to determine if the bias was significant for each of the BP parameters (mean test
value = 0); again, all three null hypotheses were rejected (p<0.05). Additionally, the SD
for the mean difference of SBP was 12.8, for DBP was 10.2, and for MAP was 11.2, and
the width of the CIs was quite large for all three BP parameters. For example, the SBP
LCL was -28.9 mmHg, and UCL was 21.4 mmHg; therefore, the width between the LCL
and UCL comprised 50.3 mmHg for SBP. Similarly, the width between DBP LCL and
UCL was 40.0 mmHg, and the width between MAP LCL and UCL was 44 mmHg. With
such a significant variation between mean manual and mean NIBP measures, a
determination that the two methods of measurements are in agreement would be
questionable.
Using SBP as an example, poor agreement is evident in both the SBP’s 50-point
range in CIs and the BP data points wide dispersion and deviation from the centerline of
equality on the linear scatter plot. Interestingly, the error increased at approximately 130
mmHg levels, and this trend continued as the SBP increased. Because AIS patients
commonly present with severe hypertension that requires treatment with antihypertension
agents before thrombolysis can be initiated, it may be likely that in hyperacute ischemic
stroke the error between manual and NIBP devices may be quite substantial.
Undoubtedly this error impacts clinical treatment decisions and the subsequent
management required to provide safe patient care, and it may also result in clinicians
maintaining BP much lower than the original limits of 180/105 mm Hg.
Investigators who also studied agreement between NIBP and manual or arterial
measurements40,43,114,115,119,144 evaluated their results based on the limits set by the
Association for the Advancement of Medical Instrumentation (AAMI).103 However, the
AAMI procedure is intended for validation of an individual NIBP device’s accuracy prior
to placing the device into clinical use. The AAMI procedure involves testing the mean
error and the SD of the error for a total of 255 pairs of measurements (three sets of
manual BP and NIBP measures) from 85 patients. Per the AAMI, an acceptable limit is
when the difference of the means between manual and NIBP measures <5 mmHg with
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SD <8. Should BP investigators and clinicians consider AAMI protocol to be the gold
standard for patient treatment decisions as well? Or should acceptable LoA, mean
difference, and SD be studied, evaluated alongside the clinical condition in question, and
ultimately agreed upon by subject matter experts? AAMI seems to support the latter,
stating in their 2013 publication of recommendations for the basic safety and essential
performance of automated non-invasive sphygmomanometers:
…the application of a standard or recommended practice is solely within
the discretion and professional judgment of the user of the document. A
standard or recommended practice is limited, however, in the sense that
it responds generally to perceived risks and conditions that may not always
be relevant to specific situations. A standard or recommended practice is
an important reference in responsible decision-making, but it should never
replace responsible decision-making.103(p. 2)
A related problem in relying on AAMI procedures to determine accuracy and
agreement of readings between manual and NIBP measurements is that algorithms,
testing, and validation procedures differ from one device to another103 and are scattered in
many different publications or patents.105 This means that claims and findings of
accuracy and agreement for one NIBP device brand cannot be generalized to other
brands. Babbs,31 an NIBP device engineer, confirms this situation when reporting that
accurate extraction of systolic and diastolic pressure oscillations remains an open
problem in biomedical engineering. To resolve this problem, he developed an algorithm
based on physics and physiology and then shared it in the public domain for NIBP device
manufacturers and engineers to review and use.
Many clinicians are unaware that NIBP devices are engineered in a way that
should make the MAP the most accurate measurements from these devices. Similar to
Kiers et al.,121 we also found a relatively large range in the difference between calculated
and measured MAP between manual and NIBP measures. Kiers et al.121 and our results
challenge the well-held belief that MAP is the most accurate measure from the NIBP,
unless we are to accept that manual measurement in and of itself is flawed and inaccurate.
Even if we were to accept the NIBP MAP as the most valid measure, this still presents
the problem that SBP and DBP values differ significantly, with hundreds of combinations
of SBP and DBP values possible from a single MAP measurement.
An Alternate Approach to Measure Agreement
The British Hypertension Society (BHS) introduced a protocol for evaluating
NIBP devices’ accuracy by using the percentage of differences within certain limits.131,141
The BHS protocol is quite complex, and similar to the AAMI procedure, its intent is to
evaluate the accuracy of an NIBP device prior to placing it into service. The NIBP
device is graded A, B, C, or D based on percentages of readings within 5, 10, and 15
mmHg. The BHS protocol also includes an instruction to determine whether the mean
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differences and SD fall within the AAMI recommendations of <5 mmHg and <8 mmHg,
respectively.
We adapted a portion of the BHS protocol to determine in percentage terms how
far each of the 475 paired manual and NIBP measurements fell from each other. We also
evaluated our findings with an adaptation of the protocol guidelines that stipulates that
80% of measures should fall within 5 mmHg, and 95% should fall within 10 mmHg.141
We found only 39% of the 475 sets of SBP manual and NIBP measures fell within 5
mmHg of each other, 62% fell within 10 mmHg, and 86% fell within 20 mmHg of each
other. For DBP, 44% fell within 5 mmHg of each other, 72% fell within 10 mmHg, and
95% within 20 mmHg each other. For MAP, 34% fell within 5 mmHg of each other,
62% fell within 10 mmHg, and 89% within 20 mmHg of each other. Importantly, none
of the 3 BP parameters had 80% of their paired measures falling within 5 mmHg and
95% within 10 mmHg of each other.
Statistical and Clinical Significance of Our Study
In their 1986 article “Statistical Methods for Assessing Agreement Between Two
Methods of Clinical Measurement,” Bland and Altman wrote:
It is most unlikely that different methods will agree exactly, by giving
the identical result for all individuals. We want to know by how much
the new method is likely to differ from the old: if this is not enough to
cause problems in clinical interpretation we can replace the old method
by the new or use the two interchangeably.130(p 308)
Clinical Significance of NIBP Measure
Alteplase significantly improves the overall odds of a good stroke outcome when
delivered within 4.5 hours of stroke onset, with earlier treatment associated with greater
proportional benefits.145 Progressive disappearance of the ischemic penumbra is the
major factor that accounts for the declining benefit with time.146 Therefore, it is
imperative that clinicians understand and consider the origins of NIBP device readings so
that treatment is not unnecessarily delayed. Per stroke guidelines, a clinician should hold
the alteplase bolus until the patient’s SBP is <185 mm Hg and DBP is <110 mm Hg, and
BP should be further lowered to SBP <180 mm Hg and DBP <105 mm Hg by the time
the alteplase infusion begins. Depending on the point in the AIS clinical pathway that the
patient’s BP is measured, the presence of bias between the means can be either clinically
significant or clinically insignificant. For example, an SBP of 180 mm Hg from an NIBP
device in a clinically stable AIS patient on arrival to the emergency department is likely
clinically insignificant in that an alteplase treatment decision is yet to be made, with
guidelines suggesting that AIS patients can be managed up to an SBP of 220 mm Hg and
DBP of 120 mm Hg when alteplase is withheld; therefore, there is no real concern if the
NIBP measurement is falsely elevated. On the other hand, the lack of agreement is
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arguably clinically significant at the point in the clinical pathway when the patient is
deemed appropriate for alteplase treatment because an SBP that is higher than
recommended stroke guideline treatment thresholds will trigger potential delays in
alteplase treatment due to the need for administration of intravenous antihypertensives.
Interestingly, higher NIBP readings may be causing practitioners to keep BP much lower
than the original alteplase treatment BP targets without their knowledge of doing so. In a
similar study of agreement between manual and NIBP measures of pre-assessment of
outpatient surgery patients, Coe et al.120 surmised that 6.5% of their study participants
would have been inappropriately diagnosed as hypertensive from the NIBP device
readings, and thus potentially rejected from day surgery and inappropriately referred to
their general practitioner. In agreement with Cole’s suggestion, it would be reasonable
for acute stroke practitioners to recheck an acute AIS patient’s BP using a manual
sphygmomanometer for any hypertensive reading by an NIBP device.120
To further examine the potential influence manual and NIBP measures may have
on clinical decision making, we analyzed our paired measures to determine the number of
measurements that fell within the in-bounds and out-of-bounds limits for initiation of
alteplase. For SBP, 11 manual and 22 NIBP measures were >180 mmHg, meaning that
alteplase treatment would have been delayed more often in the NIBP group due to SBP
>180 mmHg. None of the DBP values we measured for either manual or NIBP
exceeded the guideline’s 105 mm Hg threshold.
Currently, MAP is not cited in the guidelines as a measure requirement for
determining alteplase treatment thresholds; however, it can be calculated from the
180/105 mmHg exclusion boundary for alteplase treatment at 130 mm Hg. Whether MAP
of >130 mm Hg is the “true” high limit for alteplase treatment remains unknown since
even the guideline’s 180/105 mmHg values were not derived through any systematic
study of alteplase-treated patients or animals. However, assuming 130 mm Hg to be the
upper limit, 2 manual and 30 NIBP MAP measures in our study exceeded this value.
Ultimately our data were insufficient to analyze the impact of MAP on patient
outcomes. Similar to current reported performance of alteplase, only 3% of our study
population (3 patients) developed sICH. We did find that sICH patients had clinically
important but not statistically significant differences in NIHSS and mRS at discharge or 7
days, with the lack of statistical significance attributed to the small sample size. Of the
95 patients, 1 patient died, which was attributed to post-alteplase sICH. Collectively for
5 patients (3 sICH of which 1 died, plus 2 other patients that died), there were no
recorded manual MAP >130 mmHg, but there were 3 recorded NIBP MAP >130 mmHg
in 1 of the 5 patients who died in hospital but did not have a sICH; however, the overall
mean for this small group’s NIBP MAP was <130 mm Hg.
We also dichotomized patients into groups based on favorable (mRS <2) or poor
(mRS 3-6) outcomes, finding significantly higher SBP on both manual (p = 0.04) and
NIBP (p = 0.08) readings in patients with poor functional outcome at discharge or day 7.
This is similar to what others have found in their examination of BP and outcome, in that
significantly higher BP is associated with worse functional outcome.147,148
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Additional Considerations Regarding NIBP Devices
As explained in chapter 1, the NINDS study protocol required BP to be measured
manually. 4 Ultimately, recommendations in the original AIS guidelines were informed
by the NINDS study protocol. Interestingly, subsequent updates to the AIS guidelines
have yet to address and formally recommend the use of an NIBP device as an option for
BP measurement. However, the reality of clinical practice today is that manual BP cuffs
are rarely used or even available when an alteplase treatment decision is being made or
during the peri-treatment period when BP should be closely monitored and managed.
Additionally, whether NIBP devices are being used in an evidence-based manner is
debatable, given that many clinicians are not aware of the need to revert to manual BP
when a patient presents with common NIBP exclusions such as atrial fibrillation.
NIBP’s convenience, ease of use, and vast quantity and availability in hospitals
make it unrealistic to expect clinicians to return to and rely solely upon manual BP
measurements for the initiation of alteplase. Many clinicians who were practicing before
and during the 1990s when manual BP measurement was standard of care are no longer
at the bedside. Today’s clinicians are likely to question why it matters whether BP is
obtained via manual or NIBP methods, as their training included instruction on NIBP
devices.
When NIBP devices were first introduced into acute care hospitals and
ambulatory clinics, training consisted of placing the cuff, turning on the device, pressing
start, and possibly learning to set automatic repeat BP measures. Even today, training on
the use of NIBPs does not include how devices are engineered to generate the measures
or how to routinely assess whether clinically important differences between manual and
NIBP might be present. Therefore few clinicians realize that 1) certain medical
conditions make NIBP measures unreliable, 2) NIBP devices are engineered using tightly
held, proprietary algorithms, 3) MAP is accepted as the most accurate value derived from
NIBP measurements32 because SBP and DBP are algorithmically derived from the
MAP99,100 and 4) NIBP DBP more closely agrees with manual measurements, than SBP.
We surmise that still today, little has changed regarding clinicians’ degree of
understanding of NIBP measures, particularly pertaining to how well measures from the
NIBP device actually agree with manual BP measurements.
During the time that the NINDS study protocol and subsequent AIS guidelines
were written, 4 research examining optimal MAP in AIS patients was scarce, and BP
measurements by manual sphygmomanometer were standard of care. Additionally, few
neurologists managed BP in acute stroke patients during the 1990s, instead relying on
internal medicine and emergency specialists to oversee the general medical management
needs of AIS patients. Certainly, these two factors likely contributed to a lack of
awareness of the value of MAP and its absence from mention in current guidelines.
However, since then, NIBP devices that display MAP alongside SBP and DBP have
become standard of care in hospitals throughout the United States and most of the world,
although to date, most stroke clinicians fail to pay attention to the MAP measure, instead
favoring SBP and DBP for treatment parameters. Despite the universal adoption of NIBP

54

devices over the last 25 years, there continues to be a paucity of literature related to a
goal MAP in AIS patients. To further this area of research, it will also be necessary to
understand more about practitioners’ overall physiologic knowledge of BP-derived
variables, as well as to understand the availability of manual devices in settings where
NIBP now dominates.
Study Limitations
Our study has limitations that must be acknowledged. First, we deliberately did
not interfere with alteplase treatment in our collection of study data, choosing to obtain
our sets of measures at a time that did not slow our stroke team members’ delivery of the
bolus and intravenous infusion. Additionally, we did not obtain continuous measures
over the 24-hour period as this would have been significantly labor-intensive. Because of
this, we do not have BP values collected at the time of clinical deterioration in our 3 sICH
patients, and this limited our understanding of what may have been important BP changes
during the hemorrhage period. However, continuous measurement of BP values was not
necessary to meet our study objective. Therefore, we would argue that for this phase of
study, our methods were acceptable.
A second limitation with our methods was that NIBP device brands differed
between the NJ and TN study sites, which arguably affects the generalizability of this
study. However, 100% of our study’s devices had been approved for use by biomedical
engineering and displayed current labels showing the monitoring time period for which
they were approved. We believe that while this is a limitation, it is also reflective of “real
life” monitoring, as there will always be differences in the devices used at different
hospitals. Essentially the recognition of this limitation shines a light on the fact that AIS
treatment decisions are based on device-dependent measurements that will always vary
from hospital to hospital. Past AAMI recommendations103 and the recent Association for
the Advancement of Medical Instrumentation/European Society of Hypertension/
International Organization for Standardization (AAMI/ESH/ISO) Collaborative
Statement101 summarizes nine key aspects for healthcare institutions to follow for the
validation procedure for NIBP devices. The procedure calls for three sets of manual and
NIBP measures in 85 patients for a total of 255 pairs of measurements. It is doubtful that
health care sites are validating all of their NIBP devices in this way before placing them
into service, and even less doubtful that specific populations of patients, for example AIS,
are used as part of a validation process within hospitals. Therefore, we chose to focus our
study methods on ensuring the accuracy of BP measurement techniques for both manual
and NIBP measures, and further ensured accuracy by using a dual-auscultation
stethoscope for all manual measures.
Lastly, while arterial line measurement of BP is commonly referred to as the
“gold standard” for determination of “true” SBP, DBP, and MAP values, we chose to use
manual sphygomomanometry as the point of comparison with NIBP. While this may be
considered a shortcoming in our approach, it is consistent with the methods used in the
original NINDS rt-PA Stroke Study, which established the BP parameters that are still in
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use today for alteplase treatment. Additionally, arterial lines are deliberately not inserted
in patients that have received alteplase. In fact, guidelines recommend avoiding arterial
and even venous punctures due to the fibrinolytic action of the drug, which could result in
unnecessary blood loss. It also would have been unrealistic to consent patients and
perform arterial line insertion prior to administration of alteplase as this would have
delayed time to alteplase treatment substantially, as well as increased the risk for bleeding
from failed arterial line insertion attempts. Therefore, to answer the agreement question,
we believe that our approach was realistic, in the patient’s best interest, and consistent
with the original clinical trial methods that led to use of guideline BP thresholds.
Conclusion
Despite the widespread use of NIBP devices, few clinicians are familiar with its
fundamental operating principles and of the potential for inaccuracies and disagreement
between manual and NIBP measurements.149 In their 2019 scientific statement, the
American Heart Association (AHA) wrote that there is little, if any, evidence available on
the validation of BP measurements obtained in the acute care setting.150 Despite the
AHA’s acknowledgment of lack of knowledge regarding BP monitoring, acute stroke
practitioners trust and rely on NIBP devices to guide AIS patient treatment. Our results
show that NIBP measures are consistently higher than, and may differ from manual
measurements as much as 50 mmHg for SBP, 40 mmHg for DBP, and 44 mmHg for
MAP, and that this disagreement may cause treatment delays due to the need to manage
hypertension.
The safe MAP for AIS patients receiving alteplase treatment is not yet known, but
work must continue in this area. Acute stroke practitioners are encouraged to begin
exploration of MAP due to their use of and reliance on NIBP to guide AIS treatment.150
This research must be guided by consensus for acceptable levels of BP agreement as well
as determination of validation methods that realistically fit within the current treatment
and monitoring paradigm and do not disrupt time to alteplase administration. It is likely
that stroke guidelines are silent regarding MAP because the information to understand
safe MAP levels in AIS patients during and after alteplase administration is lacking. Our
study takes an important first step in reframing AIS treatment context toward
consideration of MAP as a key measure to guide the initiation of alteplase treatment and
ongoing patient management.
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